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Abstract
Magnetic Resonance Imaging (MRI) is a non-invasive technique used in medical imaging
with applications in diagnosis, stage determination and monitoring of the progress of disease.
Although contrast agents have been used to enhance the image generated by MRI, it still
suffers the major shortcoming of low sensitivity. This has led to a thrust to develop contrast
agents that improve the sensitivity by relaxation (T1 and T2) as well as by chemical exchange
saturation transfer (CEST).
To further aid in the development of sensitive MRI contrast agents, the synthesis and
evaluation of lanthanide and transition metal complexes was executed. The results are
presented herein.
Chapter 2 investigated pH dependent reversible binding on CEST effect and relaxivity in
macrocyclic complexes possessing three of the same arms and a lone p-nitrophenol arm.
Unfortunately, only the Tb3+complex had a small CEST signal. T1 relaxivity of the
Gd3+ complex showed high relaxivity at acidic pH and low relaxivity at basic pH.
Chapter 3 discussed the rigidification of the DOTAM structure as a means to promote the
formation of the SAP isomer for CEST signal generation. These ligands were rigidified by at
least one cyclohexyl group and were found to be very selective toward transition metals over
lanthanides. However, none of the complexes investigated generated a CEST signal.
Chapter 4 attempted to examine the amide CEST signal of DOTAM-tetraanilide complexes
containing various para-substituents that would limit T2 exchange and increase amide-based
pH measurements. Due to the insolubility of the other complexes, only the p-H and p-OMe
complexes were evaluated. The CEST spectrum of the Tm3+-p-OMe complex revealed two
amide signals. The absence of a bound water molecule in the Tm3+ agents allowed for higher
signal to noise ratios because of reduced T1 and T2 relaxation.
Chapter 5 involved a model study that assessed the electronic effects of para-substituents on
the amide CEST signal and relaxivity of DO3A-monoanilide complexes. CEST spectra of
3+

only the Tm complexes could be acquired. The various substituents allowed a CEST effect
ii

3+

to be observed at different pH values. The T1 relaxivities of the Dy

3+

and Tm

complexes

were both low, while the Dy3+ complexes had much higher T2 relaxivities as compared to the
Tm3+-based ones.
Finally, Chapter 6 highlighted the attempt to synthesize para-phosphonate monoanilide
analogues of the DOTAM tetraanilide complexes mentioned in Chapter 4, which would be
suitable for in vivo studies. It is anticipated that the two amide signals seen in the CEST
spectrum of the Tm3+-p-OMe complex would still persist in the modified complex, thus
providing a means of a concentration independent ratiometric analysis of the CEST effect.
Due to synthetic challenges, the synthesis of these modified complexes is still ongoing.

Keywords
Magnetic resonance imaging; Chemical exchange saturation transfer (CEST); Paramagnetic
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Chapter 1
1

Introduction

1.1 Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) is a practical tool in diagnostic medicine, used for
viewing anatomical images. This non-invasive methodology produces images based on
the relaxation rate of water protons that are ubiquitous within the body.1 Within the
clinical setting, a subject is placed in an immobile magnetic field (B0) which causes the
nuclei containing the protons to precess or rotate at a particular frequency. This frequency
is dependent on two factors, namely the strength of B0 and the gyromagnetic ratio (γ) of
the nucleus, which in this case is 1H (γH = 26.752 X 107 rad s−1 T −1).2 The spin energy
levels of the nuclei within this static magnetic field will be non-degenerate, thus a
Boltzmann distribution of the nuclei will persist. There will be more nuclei occupying the
low energy (α) state in which the spins are parallel to B0, than the high energy (β) state in
which the spins are anti-parallel to B0 (Figure 1.1a).

Figure 1.1: Diagram showing the distributions of nuclear spins in a magnetic field,
Bo (a) Boltzmann distribution with more spins in lower energy α level than higher
energy β level (b) excited state after rf pulse and (c) return to thermal equilibrium.
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The nuclei in a state of thermal equilibrium can be re-distributed between the two energy
levels by application of a radio-frequency (rf) pulse with the appropriate energy, ∆E = hυ
(where h is Planck's constant and υ is the resonance frequency).2, 3 In other words, this
radiation pulse must occur at the Larmor (resonance) frequency (υ, whereby υ = γB0) of
the system.3 Once the pulse is applied, the distribution of nuclei in the excited state
allows equal populations of nuclei between the α and β energy levels (Figure 1.1b).3
Additionally, the spins of the nuclei will be the same so that phase coherence may be
achieved.3 After some time, the system will return to thermal equilibrium and the
Boltzmann distribution will be re-established (Figure 1.1c).

1.2 Relaxation and Relaxivity
The rate at which the system returns to thermal equilibrium after irradiation by 90o rf
pulse is termed relaxation, namely T1 (spin-lattice or longitudinal) and T2 (spin-spin or
transverse) relaxation. Figure 1.2a-c shows the vector diagrams representing these
processes. At thermal equilibrium, the net magnetization is in the longitudinal (z)
direction (M0 = Mz) and once the rf pulse (B1) is applied, the magnetization flips into the
transverse (xy) plane.4 This causes a reduction of Mz and an increase in Mxy. The
magnetization of Mxy will precess around the z-axis, thus causing a decrease in Mxy and
the subsequent return to equilibrium, where M0 = Mz.
The T1 relaxation rate (1/T1) refers to the rate at which the system returns to Boltzmann
distribution while the T2 relaxation rate (1/T2) refers to the rate at which the system loses
phase coherence (Figure 1.2d-e).4 Associated with T2 relaxation is T2* relaxation,
resulting from the inhomogeneity of the magnetic field. This effect may cause the
magnetization in the xy plane to relax at a much faster rate, than is expected.
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Figure 1.2: Vector diagrams representing (a) net magnetization M0 at equilibrium
when the spins are placed in the external magnetic field B0 (b) perpendicular RF
pulse (B1) is applied that flips the magnetization into the xy plane (c) magnetization
returning to equilibrium (d) T1 relaxation (return to equilibrium in the z plane) and
(e) T2 relaxation (return to equilibrium in the xy plane). Adapted from Ref. 4 with
permission of John Wiley and Sons.

Contrast agents can be used to alter both the T1 or T2 relaxation times of water protons
and subsequently, the rates of relaxation. The designation of the type of relaxation agent
depends on a percentage basis by which that particular rate is altered.5 Contrast agents
that increase the longitudanal relaxation rate in tissue faster than they do the transverse
rate, are classified as T1 contrast agents.5 These agents enhance the MRI image generated
by increasing the signal intensity, thus they are also known as positive contrast agents.
Conversely, T2 contrast agents are known as negative contrast agents because they reduce
the signal intensity of the tissue, whilst increasing the transverse relaxation rate.5
MRI contrast agents are normally small, metal-containing macrocyclic or linear chelates.
The metals used may be paramagnetic, superparamagnetic or ferromagnetic in trait.
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Ferromagnetic agents contain iron oxide particles and are T2 shortening while
paramagnetic agents containing gadolinium (Gd3+) are T1 shortening.5 Contrast agents
containing Gd3+ (Figure 1.3) are the most widely used contrast agents within the clinical
setting, based on their approval by regulatory health agencies. Nevertheless, there have
been other agents based on manganese and iron that have been also approved for use in
similar settings (Figure 1.3).
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Figure 1.3: Chemical structures of examples of MRI contrast agents.

Gadolinium is a lanthanide and its efficiency as a paramagnetic metal in T1 contrast
agents is derived from the seven unpaired electrons it possesses in its 4f-orbitals. The
ground state of Gd3+ is symmetric, in that, each electron occupies an f-orbital, resulting in
long electronic relaxation times.1 Direct contact between the water molecule(s) bound to
Gd3+ and its unpaired electrons (dipole-dipole interaction) results in transference of the
electronic magnetization.6 This in turn, reduces the relaxation time of the water molecule
bound to the metal center.6
Relaxivity refers to the change in the relaxation rate of water protons per millimolar of
contrast agent used, as shown in equation 1.15:
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r1,2 = [(1/T1,2)obs - (1/T1,2)W]
[CA]

equation 1.1

where, r1,2 is the relaxivity, based on 1/T1 or 1/T2, respectively and [CA] is the
concentration of contrast agent. The subscript "obs" refers to the rate with the CA present
while "W" refers to the rate with pure water.
Relaxivity can be classified into two main categories: inner-sphere and outer sphere.
Inner-sphere coordination refers to the water molecule bound directly to the metal.5 This
water molecule can be influenced by the inner-sphere relaxation that in turn is dependent
on several factors. Firstly, it is possible to increase the relaxivity due to inner sphere
coordination by increasing the number of water molecules (q) that are bound to the metal,
as represented by equation 1.25:

r1IS =

q/[H2O]
(T1m + τm)

equation 1.2

where [H2O] is the concentration of water in mM, T1m is the T1 of the inner-sphere water
and τm is the residency time of that inner-sphere water molecule.5
Secondly, the water molecules are also influenced by the the electronic properties of the
metal within the chelate, as was discussed earlier. Thirdly, is the rate of water exchange.
A requirement for an effective relaxivity agent is fast exchange of the bound water
molecule with the bulk water. However, there is a balance at which this rate should
occur; too fast and the water molecule does not bind to the metal long enough to be
relaxed and too slow means that the effect of relaxation is ineffectively transmitted to the
bulk water.5
Fourthly, the rotational diffusion of the complex must be well thought-out. Smaller
molecules have shorter correlations times due to rotation (τR) and larger molecules have
longer τR, thus the latter is more efficient at promoting the desired relaxation.5 Lastly, it
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may be possible to increase the relaxivity by decreasing the distance between the metal
and the bound water proton.5
These factors also help govern T1m and are taken into account by the equations of
paramagnetic relaxation theory derived by Solomon, Bloembergen and Morgan and can
be used to predict high relaxivities of contrast agents.7-11 Further details about those
equations are outside the scope of this thesis and it is the author's belief that the content
within this thesis does not warrant further discussion of those equations for
comprehension of the remainder of the material.
Second sphere coordination pertains to the protons of the hydrating water molecules of
the complex and its contribution to relaxivity depends on the temperature and the external
magnetic field.5 Closely related to second sphere relaxivity (and sometimes difficult to
differentiate) is that of outer-sphere relaxivity, which pertains to the water molecules that
diffuse near the metal center. It is important to note that the size of the second sphere
(and outer sphere) contribution to the overall relaxivity is very challenging to predict.5 A
summary of the afore-mentioned parameters that influences relaxivity is presented in
Figure 1.4.5

Figure 1.4: Molecular considerations that influence relaxivity. Reprinted from
Ref. 5 with permission of The Royal Society of Chemistry.
The T1 agents currently in use are excellent as blood pool or extracellular T1 agents but
they have limited success as responsive agents in vivo. The T1 change in vivo is non-
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linearly dependent on concentration. This phenomenon is due to several reasons such as
the inconsistent distribution of the contrast agent within the biological system, the pulse
sequences used to generate the signal as well as protein binding and differences in
viscosity.5 Additionally, these contrast agents are never completely silent. This drawback
means that a signal is generated even if water cannot access the metal center, thus making
it difficult to tell whether the change is due to relaxivity or concentration.12 The detection
of the agent is a function of the environment and is directly proportional to concentration,
which is usually unknown in vivo.13
Omniscan (Figure 1.3), which is a Gd3+-DTPA complex has a stability constant of 22.46,
while Dotarem and Prohance have stability constants of 24.7 and 23.8, respectively at
25oC.14 The higher stability constants for Dotarem and Prohance is attributed to the
macrocyclic effect, wherein the stability of a macrocyclic metal complex is higher than
that of a complex formed from the analogous monodentate ligands.14 While these agents
generally have an excellent safety profile, patients that have less than perfect kidney
function may develop nephrogenic systemic fibrosis, after taking gadolinium based
agents. If the kidneys are unable to properly filter waste from the blood, the contrast
agent will spend a longer time in the body and is likely to undergo transmetalation with
endogenous ions such as Zn2+, Cu2+ and Ca2+. The uncomplexed Gd3+ aqua ion is very
toxic, with an LD50 of 0.1-0.2 mmol kg-1 in small animals.14 The toxicity is due to the
similarity to Ca2+ in size, coordination number and Lewis acidity.
These disadvantages have led to the need for more effective contrast agents that will be
both sensitive to physiological changes whilst maintaining the contrast enhancement.

1.3 Chemical Exchange Saturation Transfer (CEST)
A more recent alternative to T1 contrast proposed by Ward et al., termed Chemical
Exchange Saturation Transfer (CEST), has been fundamental in the discovery of new
contrast agents.15 Earlier experiments referred to this as Saturation Transfer (ST) or
Magnetization Transfer (MT). CEST involves exchange between protons of solutes and
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bulk water, while MT occurs between semi-solid macromolecules and bulk water.15,

16

The contrast generated by MT can arise by either cross-relaxation or a combination of
cross-relaxation and chemical exchange.17-20 CEST agents operate by reducing the water
proton signal through a chemical exchange site on an agent. This exchange of protons
must occur between two magnetically different environments.15 Common sites of
exchange are -NH (of amines or amides) and -OH (of alcohols).
For a CEST agent to be effective it must meet two criteria. Firstly, the exchange rate (kex)
which is affected by pH, temperature and the ionic environment should be smaller than
the chemical shift difference (Δω), that is, Δω >> kex.15 This consequently means that
residence proton lifetime, τm should be about 10-5 - 10-2 s, thus translating to the rate
falling within the slow to intermediate range. 16, 21
Secondly, a CEST agent also requires a large Δω from the bulk water signal.

15

This

feature, if met, offers several advantages. If the Δω is large, then a greater chemical
exchange is allowed, provided it remains within the exchange boundary.14 This should
then produce a larger CEST effect. A larger Δω also allows for specificity of the
radiofrequency pulse needed to achieve saturation of the agent without directly affecting
other protons.15, 16 In addition, there is a reduction in the macromolecular MT background
effect which always accompanies CEST in tissues. 15
Figure 1.5 shows a schematic diagram describing the process of CEST.

22

As shown,

there are two pools of exchangeable protons but it should be noted that three and four
pool models have also been described.

23

Here, pool A represents the exchangeable

protons of the bulk water and pool B represents those belonging to the contrast agent. At
equilibrium, there is a Boltzmann distribution of the nuclei within both pools. A
presaturation pulse is applied at the resonance frequency of the pool B protons, which
then causes saturation of said protons and promotion of some nuclei to the higher energy
level. This saturation is then transferred by the exchange of nuclei occurs between pool A
and pool B. As a result, when the signal is acquired, there is a reduction in the signal due
to the bulk water pool A protons. After some time, the nuclei of pool A will return to
equilibrium. As can be seen in Figure 1.5, relaxation may be a competing process with
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chemical exchange. Hence, the CEST effect will only be seen if the protons of pool B
have long relaxation times with respect to their exchange rates.

Figure 1.5: A schematic representation of both relaxation and CEST processes.
Pool B represents the exchangeable protons of the contrast agent and Pool A
represents the bulk water. The distribution of spins in Pool B is altered by
application of a presaturation pulse to that pool. Relaxation will dominate
dominate when the relaxation rate is faster than the chemical exchange rate and a
normal NMR spectrum will be obtained. If chemical exchange is faster, then
chemical exchange will cause redistribution of spins in both pools, thereby
reducing the bulk magnetization of Pool A. Reprinted from Ref. 22 with
permission of The Royal Society of Chemistry.

A CEST spectrum or Z spectrum is generated by selectively saturating a particular proton
signal of the contrast agent (Ms) with a radiofrequency pulse, thus generating an image
(Figure 1.6).16 However, another image is needed because the contrast to noise ratio is
limited. A similar pulse is applied on the opposite side of the water resonance (M0),
therefore this second image will be without the CEST effect. The images obtained after
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each pulse application are subtracted and a CEST image is obtained which shows a
darkening or negative contrast due to the contrast agent. The CEST effect is represented
as a percent decrease in the total bulk water intensity and is shown in the equation 1.3 16:
CEST effect (%) = (1 - Ms/ M0) x 100

equation 1.3

Figure 1.6: A simulated CEST or Z-spectrum for a two-pool exchanging system.
Pool A is at 0 ppm and Pool B at 25 ppm. Reprinted from Ref. 16 with permission of
The American Chemical Society Publications.

A CEST agent is highly beneficial as compared to other conventional relaxation contrast
agents. Firstly, one can turn the contrast effect on and off as desired, either by turning the
presaturation pulse off or changing its frequency.16 Secondly, based on the method of
acquisition, there is no need to obtain pre- and post-contrast images, a process necessary
to eliminate artifacts due to motion.24 Although two images are needed for a CEST
spectrum, they can be obtained simultaneously. Furthermore, multiple agents with
exchangeable protons of different chemical shifts can be designed.16 Additionally, CEST
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contrast has a high contrast to noise ratio that can even be attained at high magnetic
fields.25

1.4 Diamagnetic Chemical Exchange Saturation Transfer
(DIACEST)
The molecules that were initially used to generate a CEST effect were diamagnetic, and
thus known as DIACEST agents.15 DIACEST agents represent one main class of CEST
agents (the other will be discussed in the following section). In general, DIACEST agents
may take the form of endogenous or exogenous macromolecules and small molecules
such as glucosaminoglycans, sugars, amino acids, and heterocyclic compounds (Figure
1.7).
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Figure 1.7: Examples of DIACEST agents.

While these agents are sensitive to factors such as pH and temperature, they are faced
with a major drawback, that is, the size of their Δω. DIACEST agents have Δω < 6 ppm ,
therefore the bulk water signal tends to interfere with the signal generated from such
agents.15, 16
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1.5 Paramagnetic Chemical Exchange Saturation Transfer
(PARACEST)
1.5.1 Lanthanide-based PARACEST
The principles of CEST have been fundamental in the discovery of other contrast agents
known as Paramagnetic CEST (PARACEST) agents.26-30 PARCACEST agents represent
the second main class of CEST agents. These complexes contain paramagnetic metals
such as lanthanides. The use of lanthanides as the paramagnetic metal of choice may be
based upon the location of the unpaired electrons. In comparison to the paramagnetic 3dblock transition metals that have their unpaired electrons in the d-orbitals, the unpaired
electrons of the lanthanides reside in their 4f-orbitals. The 4f-orbitals do not overlap with
the orbitals of the ligands, thus the bonding of lanthanides tend to be ionic. Due to their
larger size, they may coordinate nine to twelve ligands. However, their coordination
geometry is dependent on steric, rather than electronic factors.
The magnetic properties of lanthanides vary along the period since each metal contains a
different number of unpaired electrons. As such, each metal possesses a different
magnetic moment (measurement of magnetism) and magnetic susceptibility. This latter
feature influences the direction and magnitude of the interaction between the external
magnetic field and the magnetic moment.16 The magnetic susceptibility also governs the
lanthanide induced shifts (LIS) of the metals.16 It is this latter property that makes
PARACEST agents more advantageous over DIACEST agents: the LIS favourably
induces a larger Δω from the water signal.16 The larger Δω allows for a faster exchange
rate of the exchangeable protons, which now includes a water molecule that may be
bound to the metal. A larger Δω in conjunction with a faster exchange rate will only hold
true if the slow to intermediate exchange condition is maintained.22 An agent possessing
both of these properties permits more spins to be transferred within a particular time
frame.22
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Figure 1.8: (a) CEST spectrum of Eu3+-DOTAM-gly-Et (EuDOTA-4AmCE3+) [63
mM] in aqueous solution at pH 7, rf presaturation applied for 1 s, B0 = 4.7 T, B1 =
16.4 db at 22°C showing bound H2O at 50 ppm and (b) CEST spectrum of
DyDOTAM3+ at B0 = 9.4 T and at 25°C showing -NH at 80 ppm and bound H2O at 720 ppm. Reprinted from Ref. 22 with permission of The Royal Society of
Chemistry.
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Contrast agents that are paramagnetic metal complexes and are T1 shortening have at
least one water molecule that is coordinated to the centre of the metal, however, the rate
of exchange for such complexes is outside of the slow to intermediate limit which is
required for CEST agents.22 A slower exchange rate has been found for tetraamide
derivatives of DOTA (DOTAM) whereby all the acetate arms of DOTA have been
replaced by amide arms. The amide arms provide a reduced electron density at the metal
center, which in turn leads to the slow exchange of the exchangeable protons.16 This
structure has been rudimentary in the design of subsequent PARACEST agents.31-34
These DOTAM derivatives are moderately stable and have a high kinetic inertness that
has been thought to result from the size of the Ln3+ ion and the cavity of the preformed
macrocycle.35
Of all the lanthanides, europium (Eu3+) has been found to have the slowest rate of water
exchange and a low paramagnetic relaxation enhancement.16 These properties of Eu3+ are
favourable in the design of PARACEST agents that include the pre-saturation of bound
water.16 An example of such an agent is Eu3+-DOTAM-gly-Et (reported as EuDOTA4AmCE3+) in which the water exchange rate slowed substantially, thereby allowing for a
discrete peak to be observed which had a large Δω from bulk water (Figure 1.8a).36 A
larger CEST effect may be observed for exchangeable protons such as -NH when
compared to water as seen for the Dy3+-DOTAM complex (Figure 1.8b). 22

1.5.2 Transition metal-based PARACEST
The invention of transition metal CEST (TM-CEST) is a reasonably recent development
and as such, the foray into its application is behind that of lanthanide-based PARACEST.
The requirements for CEST based on transition metals are similar to that of lanthanidebased PARACEST. These include using a paramagnetic metal, having a slow to
intermediate exchange rate and the presence of exchangeable protons. Another similarity
with lanthanide-based CEST is the ligand design. An additional consideration for TMCEST is the number of possible oxidation numbers for the transition metals, which is not
as important for lanthanides. Another is in regards to the smaller size of the transition
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metals, which causes their coordination number to be six (as compared to nine to twelve
for the lanthanides). The transition metals that have been explored thus far for this
application include cobalt,37,

38

nickel39 and iron40-44 (Figure 1.9).45 These metals are

biologically relevant and have suitable paramagnetic properties.

a)

b)

Figure 1.9: Transition metal-based CEST due to amide protons of (a) Fe2+DOTAM-gly-Et [60mM] at pH 8.6, RF presaturation applied for 4 s, B0 = 500
MHz, B1 = 700 Hz at 25 °C and (b) Co2+-CYCLAM [10 mM] in 100mM NaCl, 20
mM HEPES, pH 7.3-7.4, rf presaturation applied for 2 s, B0 =11.7 T, B1 = 24 μT at
37 °C. Adapted from Ref. 38 and 45 with permission of The Royal Society of
Chemistry.
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1.5.3 Applications and Challenges of PARACEST agents
Since the reporting of PARACEST began, the associated agents have been shown to be
sensitive to varied environments such as pH,26, 46 temperature47, 48 and metabolites such
lactate,49 and glucose50,

51

(Figure 1.10). A desired feature of responsive PARACEST

agents entails having two different types of protons available for chemical exchange. This
feature allows a ratiometric analysis of the CEST effect due to each proton, thereby
allowing a concentration independent method of assessing these changes. Currently, there
are difficulties in designing similar probes using traditional T1 and T2 MRI agents of
which the local concentration of the agent has to be known.

Figure 1.10: Examples of responsive lanathanide-based PARACEST agents.

While there are many advantages to be gained by using PARACEST agents over
relaxivity agents, it is important to note that there are limitations that may impede the
progress to be made. One of these limitations is the earlier discussed MT effect, which in
vivo, obstructs the CEST signal as shown in Figure 1.11.53 This obstruction can be
extended to the bound water signal at 50 ppm in Eu3+ complexes.53
Another limitation of PARACEST agents is that of low sensitivity. However, efforts are
currently being made to rectify this impediment. These resolutions include increasing the
number of exchangeable protons on the contrast agent, combining the excellent shifting
ability of lanthanide complexes with the peculiar characteristics of nanovesicular systems
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(NanoCEST) and promoting the formation of non-covalent supramolecular adducts
(SupraCEST).53

Figure 1.11: Simulated spectra showing comparison between the performance of
a CEST system without (black solid curve) and with (red curve) an MTC
contribution. Reprinted from Ref. 53 with permission of John Wiley and Sons.

In order to further the optimization of PARACEST agents, it is important to consider the
agent, the solvent water, and the instrument settings.22 Subsequently, τm should be short
and the concentration of the contrast agent high as possible.22 Unfortunately, this latter
requirement is not favorable and can be compensated for by having a higher number of
exchangeable protons present in the compound. In addition, one may increase the presaturation power B1, which allows for an agent undergoing fast exchange to be
considered.22
The possibilities are endless in regards to the future of PARACEST agents and the
considerable knowledge gained about the magnetic properties of PARACEST agents thus
far, will be beneficial for further development of these agents. However, these agents will
have to be exhaustively evaluated before they can be used in the same context as current
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MRI relaxivity agents. The main barrier towards the use of PARACEST agents within a
clinical setting is the MT effect of tissues. This issue may be resolved by developing
PARACEST agents that produce a CEST signal outside of the range of this effect.

1.6 Scope of Thesis

Figure 1.12: Structure of the DOTAM scaffold on which the complexes in the
upcoming sections of the thesis are to be based.

In light of the discussion in the prior sections, the focal point of this thesis was to develop
and appraise innovative ligands that would incorporate lanthanides and transition metals
to be used as MRI contrast agents.

Such metalated complexes would fulfill the

requirements of good PARACEST agents, thus serving as promising alternatives to
relaxivity agents. These PARACEST agents were predominantly based on the DOTAM
scaffold (Figure 1.12), with variations made so as to principally analyze their various
CEST properties based on either (or both) the water molecule bound to the metal center
as well as the amide proton (s) of the pendant arm (s).
The modifications to be carried out on the DOTAM scaffold may be made on the pendant
arms or on the backbone of the macrocyclic ring (or both). Hence, Chapter 2 focused on
the synthesis and evaluation of a DOTAM analogue that had one arm replaced with a
reversible binding group that would be bound to the metal center in a pH dependent
manner. Chapter 3 targeted the preparation and analysis of the DOTAM core structure,
which had been rigidified to varying degrees on the backbone of the macrocyclic ring.
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Chapter 4 concentrated on the preparation and examination of DOTAM tetraanilines
containing varying substituents in the para-position of the aniline ring, ideal for
electronically tuning the amide protons. As a result of solubility issues with most of the
tetraanilide complexes, this led to the synthesis and investigation of para-substituted
monoanilide complexes which deviated from the DOTAM ligand, as seen in Chapter 5.
Chapter 6 details the effort made to make the soluble DOTAM tetraanilides more
biocompatible. These efforts involved synthesizing DOTAM tetraanilides that had one of
the four aniline rings possess a phosphonate group in the para-position.
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Chapter 2
2

Lanthanide DO3AM Complexes with a Reversible
Binding Arm

2.1 Introduction
In order to investigate the effect of reversible binding of one arm of the cyclen
macrocycle on the CEST effect due to the bound water or amide proton(s), a series of
asymmetric DO3AM ligands was designed and synthesized. This design envisioned the
ligands possessing three of the same acetamide arms and the fourth arm having a
potential donating group further away from the metal center. It was also hypothesized
that the lone arm would bind in a pH dependent fashion and thus the ligand would switch
between octadentate and heptadentate coordination modes.
Production of a CEST signal requires a slow exchange rate of the exchangeable protons
(lifetime, τm, of 10-5 - 10-2 s).1 This is made possible by the use of amide arms (weak
donors) which lower the electron density at the metal center, in comparison to acetate
arms.2 As a result, both the metal bound water protons and the amide protons of the
pendant arms exchange slowly with the bulk water in order to meet the electron density
requirements of the metal. This slow exchange should still be present when the
coordination by the DO3AM ligand is octadentate. The loss of a coordination site to the
metal in the heptadentate form may encourage an even slower exchange rate of the amide
protons and bound water protons. This is feasible due to the additional reduction in
electron density at the metal center. Accordingly, this further reduction may result in an
improved CEST signal. Since the electron density requirements of the metal center may
be met by the coordination of another water molecule to the metal, resulting in an
increase in relaxivity, the relaxometric properties will also be assessed.
In order to achieve the desired heptadentate/octadentate binding modes, a labile ligand
with the appropriate pKa is required. To facilitate this switch in binding, the para-
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nitrophenol group was chosen as the labile pendant arm and the other three arms were
acetamide-glycinate groups. The pKa of the para-nitrophenol group is 7.18 in water 3,
which makes it suitable for observing changes in a biological environment. Other parasubstituted phenols with electron-withdrawing groups such as chloro and cyano have
pKas of 9.38 and 7.8, respectively (in water) 3. The higher pKa values for these groups
mean that they are less suitable for use within the biologically relevant pH range. As
such, the choice of the para-nitrophenol for the lone labile arm offers the chance to
develop a potential PARACEST pH responsive probe for applications in the detection of
cancer cells, which have an acidic pH.2

Figure 2.1: Chemical structures of some complexes discussed in this work.

2.2 Results and Discussion
2.2.1 Synthesis
Scheme 2.1 represents the initial attempt to the target nitrophenol-DO3AM-gly (NPDO3AM-gly) complexes. This route involved trialkylation of cyclen with benzyl (2chloroacetyl)glycinate 2.1 as previously reported.3 However, during the synthesis,
difficulties such as poor yields were encountered. These yields stemmed from the
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incomplete conversion to the desired trialkylated product as well as over-production of
the tetraalkylated product.
Several conditions were attempted with the aim of optimizing the yield. These included
using varying equivalents of electrophile (1- 5 eq), bases (NaHCO3, Et3N, DIPEA; 0 - 10
eq), solvents (CH3CN, CH2Cl2, CH3Cl), temperatures (-40oC to 80oC) and reaction times
(up to 1 week). Additionally, the protecting group of the electrophile was changed to that
of the ethyl and tert-butyl ester. Regrettably, all these changes were unproductive.
In addition to the synthetic challenges, the purifications were also problematic. For the
reason that multiple products formed during the first step of trialkyation, purification by
column chromatography was required. The many attempts made to isolate pure
trialkylated product were unsuccessful due to the co-elution of both the tri- and
tetraalkylated products. Moreover, when HPLC purification using a C18 column was
attempted, transesterification as well as partial deprotection of the protected ester
occurred. This likely happened prior to injection because it was necessary to dissolve the
crude reaction mixture in MeOH for sample injection.
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Scheme 2.1: Potential synthetic route towards NP-DO3AM-gly complexes.
Due to the lack of success in what was expected to be a straightforward and easy
synthetic pathway to the desired metal complexes, another approach to achieve that
objective was attempted. This modification involved a reverse of the initial synthetic
steps. As such, a monoalkylation with the electrophile of the lone p-nitrophenol arm,
followed by trialkylation with the acetamide arms was performed. This sequence of steps
worked successfully as seen in Scheme 2.2. Cyclen was first protected using formyl
groups as reported to afford tri-formyl cyclen 2.3.4 Monoalkylation with 2-hydroxy-5nitrobenzyl bromide 2.4 and subsequent deprotection of the formyl groups with 2M HCl
gave the crude product 2.6. The crude mixture was precipitated with ether to give the
desired monoalkylated cyclen 2.6 in good yield. Compound 2.6 was trialkylated with
ethyl (2-chloroacetyl)glycinate 2.7 to afford compound 2.8 in moderate yield after
purification by column chromatography. The ester protecting groups were removed by
saponification and the crude mixture purified by size-exclusion column chromatography
to give the ligand 2.9 in good yield. With ligand 2.9 in hand, metalation with the
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lanthanides was done based on literature procedure and this proceeded smoothly. The
metalated complexes were purified by size-exclusion column chromatography to give the
complexes 2.10 - 2.14 in moderate yields.

Scheme 2.2: Modified synthetic route towards NP-DO3AM-gly complexes 2.10 2.14.

In order to expand the scope of the target ligand and to develop a possible redox
responsive CEST agent, we attempted to reduce ligand 2.9 (Scheme 2.3). Several
conditions shown in Table 2.1 were attempted but unfortunately, none was successful.

29

Scheme 2.3: Attempts to reduce the NO2 group of 2.9.
Table 2.1: Conditions attempted for reduction of the NO2 group of 2.9.
Conditions
(i) Pd/C, H2, 2 days
(ii) Na2S.9H2O, EtOH, rt to 50oC, 2 days
(iii) SmI2, H2O, isopropylamine, N2, rt, overnight
(iv) Zn in conc. HCl, rt to 50oC, 2 days
(v) TiCl3 (>12% in HCl), H2O/AcOH (1:1), rt, 10 mins

Results
De-benzylation
No reaction
De-benzylation
No reaction
Decomposition

2.2.2 CEST Evaluation
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Figure 2.2: CEST spectra of Tb3+-NP-DO3AM-gly 2.13. CEST spectra were
acquired at 37oC, with a 15 μT, 2 s presaturation pulse, 10 mM in D2O/H2O (9:1).

30

CEST experiments for the Eu3+, Tb3+, Tm3+ and Yb3+ metalated complexes at pH 6, 7 and
8 were carried out in D2O/H2O (9:1). Only the Tb3+ complex had a CEST signal of 3% at
28 ppm at pH 8 (Figure 2.2). The pH at which the CEST signal occurs prevents the use of
this agent as a responsive probe within the biological pH range of 7.35-7.45.
CEST intensity as a function of Ln3+ choice
As mentioned in the preceding paragraph, only the Tb3+ complex had a CEST signal,
albeit a small one. Within the lanthanide series, the size of Tb3+ is between Eu3+ and
Tm3+. As such, the signal seen for the Tb3+ complex may be a circumstance of
"Goldilocks" fitting. In this situation, the size of Tb3+ was ideal for the correct orientation
to be achieved by the phenol in order for coordination to the metal center to occur. If the
metal is big (Eu3+), there may not be enough space for the phenol to attain the correct
orientation for metal coordination. On the other hand, if the metal is small (Tm3+), then
the phenol may have more than enough space for proper orientation but then the Tm3+
becomes too labile. Considering that the corresponding DOTAM-gly complexes (Figure
2.1) did generate CEST signals,5 the lack of symmetry within these p-nitrophenol
complexes may then exacerbate both conditions and thus prevent generation of a CEST
signal as was observed for the Eu3+, Tm3+ and Yb3+ complexes.
CEST intensity as a function of pH for Tb3+-NP-DO3AM-gly 2.13
The expected trend for CEST signal due to amide protons is an increase in the CEST
effect as the pH increases. The rate-determining step for exchange of amide protons is
known to be deprotonation under base-catalyzed conditions and protonation under acidcatalyzed conditions.2 The base-catalyzed exchange occurs at a pH greater than 5.2 In
essence, the CEST effect should increase with increasing pH until a maximum signal is
achieved and the exchange rate is no longer favourable (exceeds slow to intermediate
exchange) for a CEST effect to occur. Considering that a CEST signal was seen at pH 8
and none at pH 6 and 7 (Figure 2.2), complex 2.13 demonstrated this expected trend of an
increase in CEST with increasing pH. One may expect the phenol group to be
coordinated to the metal at pH greater than 5. This assumption is based on the results of
Gd3+-NP-DO3AM (Figure 2.1) in which the phenol group did not dissociate from the
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metal, even at pH values as low as 5.6 The coordination of the phenolate group at high pH
ensured that the electron density requirements of the metal center were met. When this
occured, the ligand was octadentate and produced a CEST signal due to the amide
protons, as was observed for the Tb3+complex 2.13.
At pH 6 and 7, lack of an amide CEST signal for the Tb3+complex 2.13 may indicate one
of two things. Firstly, the phenol group may in fact be protonated and not be coordinated
to the metal center, in which case the ligand was heptadentate. Subsequently, the lowered
electron density at the metal center did not lead to a slower exchange as was anticipated,
so no CEST signal was observed. Alternatively and more likely is that the phenolate is
coordinated to the metal (in octadentate form) but the exchange rate of the amide protons
was outside of the slow to intermediate range desired for a CEST signal to be produced.
This is likely to be the case for the other complexes 2.11, 2.12 and 2.14 as well.
Chemical shift (Δω) as a function of ligand design
One of the differences between the CEST results of the Tb3+-DOTAM-gly (Figure 2.1)
and the Tb3+-NP-DO3AM-gly 2.13 is the Δω of the observed CEST signals. Previous
reports have shown that the symmetric Tb3+-DOTAM-gly complex CEST signal occurs
at 61 ppm (pH 7.4).5 On the other hand, the asymmetric Tb3+-NP-DO3AM-gly complex
2.13 had a more upfield CEST signal at 28 ppm (pH 8.02). This difference in Δω between
the complexes was most likely a result of the ligand design, rather than the pH at which
the data was acquired. At high pH, the phenol group of 2.13 is expected to be
deprotonated and therefore coordinated to the metal center. Hydroxyl groups (and by
extension phenols) are weak donors and are not expected to give a strong ligand field.7
The strength of the ligand field in turn influences the size of the hyperfine shift of the
lanthanide.7 Although Tb3+ has a large hyperfine shift,2 this effect may be over-shadowed
by the weak ligand field of the phenol group and subsequently, a small Δω is observed.
At pH 6 and 7, this small Δω would violate the criteria for PARACEST agents, leading to
the absence of a CEST signal.7
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2.2.3 Relaxometric Evaluation of Gd3+-NP-DO3AM-gly Complex
Relaxivity studies of the Gd3+-NP-DO3AM-gly complex 2.10 with respect to pH were
performed. Complex 2.10 in an aerated solution of water showed an increase in the
relaxivity as the pH decreased, with a very sharp increase between pH 5.5 and 6.5 (Figure
2.3a). The r1 value of 1.5 mM-1 s-1 at basic pH is lower than that for Gd3+-NP-DO3AM
(basic pH: 2.8 mM-1 s-1) 6 while at acidic pH, complex 2.10 has an r1 value of almost 5.3
mM-1 s-1. This value is higher than that of Gd3+-NP-DO3AM, which has an r1 value 3.4
mM-1 s-1 under similar pH.6

5.5

2.6

5.0

2.4

aerated

2.2

degassed

r1 (mM-1 s-1)

4.0
3.5

a)

3.0
2.5

r1 (mM-1 s-1)

aerated in H2O

4.5

2.0

b)

1.8
1.6
1.4

2.0

1.2

1.5

1.0

1.0
3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5

3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5

pH

pH

Figure 2.3: Relaxivity profile of 10 mM Gd3+-NP-DO3AM-gly complex 2.10 over pH
range 4 to 9, 25oC and 400 MHz in (a) H2O (aerated) and (b) 10 mM NaHCO3,
aerated (■) and H2O, degassed (●).

This relaxivity enhancement at acidic pH is not limited to complexes with amide side
arms. If one compares Gd3+-DO3A-like complexes such as Gd3+-DO3A-NO2Ph (Figure
2.1), a similar pattern is also seen. For such complexes, the relaxivity is found to be stable
between pH 5-8.8 Below that range, it may increase due to acid-catalyzed demetalation.
Above pH 8, OH- ions and dissolved CO2 in the form of carbonate can displace the bound
water molecule and cause formation of ternary adducts which leads to a decrease in
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relaxivity.8 In order to determine if carbonate binding did play a role in the relaxometric
behavior of 2.10, a study in aerated bicarbonate solution was similarly done as that
reported.9 Another experiment was done in degassed solution of H2O and compared to
that of the aerated bicarbonate solution. Figure 2.3b shows the relaxivity as a function of
pH for the degassed and aerated solutions of the Gd3+ complex 2.10 in water and sodium
bicarbonate solution, respectively. The trend in the sodium bicarbonate solution was
parallel to that previously reported for a Gd3+-DO3AM-ala complex (Figure 2.1).9
However, since the trend of complex 2.10 in degassed and aerated solutions were similar,
this possibly means bicarbonate was also being bound in the degassed solution, even after
purging with N2 for two minutes prior to collecting the data. As previously reported, one
should expect the relaxivity in degassed solution to be high and constant over the pH
range 2 - 10, indicating two waters coordinating to the metal center.9 In both solutions of
2.10 at high pH, the carbonate ion will be bound to the metal in a bidentate manner and
the metal will have all its coordination sites occupied. As a result, a water molecule
would not be coordinated to the metal. Once the pH becomes more acidic, the carbonate
ion will no longer bind to the metal and a water molecule may be coordinated instead,
leading to an increase in relaxivity.
Increases in relaxivity may also be due to the reduced distance between the metal and
bound water protons as well as short correlation times due to rotation but these values are
expected to be small for low molecular weight11 complexes like 2.10. While the
relaxivity enhancement at acidic pH could also be due to demetalation of the ligand,
thereby forming Gd[H2O]83+ (r1 = 13 mM-1s-1)11, the stability constants for Gd3+-DOTAM
and Gd3+-DOTAM-gly are 10.05 and 14.54, respectively. 12, 13 These values indicate high
stabilities for those complexes and one can infer that the stability for complex 2.10 would
be within those values. Additionally, the relaxivity increase at acidic pH may be due to
the coordination of two water molecules to the metal center as per the design of the
ligand. This would be expected to occur once the phenolate gets protonated at low pH
and no longer coordinates to Gd3+. However, in the case of Gd3+-NP-DO3AM, it was
observed that the relaxivity enhancement did not correlate with the apparent pKa of 6.48
for the phenol and an increase in relaxivity was observed at a pH below the phenol pKa.6
The pKa may be influenced by the proximity of the tri-cationic metal and the electron
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withdrawing nature of the benzylic amine-like linkage to the ligand. It is not surprising
that it is not identical to free p-nitrophenol.
The overall relaxivity enhancement of complex 2.10 at acidic pH is likely due to a
complex combination of factors such as the increase in prototropic exchange of the
phenolic protons and bound water protons 6, as well as the presence of the acetamideglycinate arms. In the latter case, these arms may form hydrogen bonds with the
surrounding water molecules and thereby increase the contribution of outer sphere
relaxation to the overall relaxivity.

2.3 Conclusion
The initial route followed towards the synthesis of a series of asymmetric complexes
having three acetamide-glycinate arms and a p-nitrophenol arm for reversible binding
was met with unexpected challenges. However, these were resolved by reversing the
order of a few earlier steps in the synthetic scheme and the desired compounds were
obtained.
CEST experiments for the Eu3+, Tb3+, Tm3+ and Yb3+ NP-DO3AM-gly complexes were
done at various pH values but only the Tb3+ complex showed an amide CEST signal at
pH 8. In comparison to the tetraglycinate complexes of the same metals, there was a
significant decrease (in the case of Tb3+) as well as elimination of the CEST effect, with
respect to the other metals. The lack of a CEST signal for the other complexes as well as
at other pH values may be due to a variety of reasons, primarily the faster than ideal
exchange rate of the amide protons (and bound water), especially when the ligand is in its
heptadentate form. This is in contrast to what was hypothesized based on the reduced
electron density at the metal center.
The increase in relaxivity at low pH in both the degassed and aerated solutions of the
Gd3+ NP-DO3AM-gly complex 2.10 is likely due to a combination of increased
prototropic exchange and or outer sphere relaxation, rather than simply an increase in the
number of water molecules coordinated to the metal center. This increase in coordinated
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water molecules would arise because of dissociation of the protonated phenol group.
Sharp increases in relaxivity within the biologically relevant pH range of 5.5 to 7.5 were
recorded for these various solutions. This does demonstrate the sensitivity of the phenol
group to act as a relaxivity-based pH sensor.
With the information gleaned here, it is now known that amide CEST can be modulated
due to reversible binding but may be strongly dependent on the metal center and perhaps
type of ligating group involved. Unfortunately, due to the small CEST effect at such high
pH, this agent is not suitable as a PARACEST pH responsive probe.

2.4 Supplemental Information
2.4.1 General Experimental
General synthetic details can be found in Appendix 1.
CEST and Relaxivity Experiments
CEST spectra were acquired on a 600 MHz vertical bore NMR spectrometer, using a 15
µT, 2s continuous wave presaturation pulse at offset frequencies ranging from -110 to
110 ppm in steps of 1 ppm at a concentration of 10 mM in D2O/H2O (9:1) at pH 6.00 ±
0.03, 7.00 ± 0.03 and 8.00 ± 0.03; 25oC or 37 °C. T1 relaxation time constant
measurements were carried out on a 400 MHz spectrometer with 10 mM of contrast agent
in H2O or in 10 mM NaHCO3 using an inversion recovery sequence (14 inversion times
in the range of 0.001 s – 0.3 s) with a minimum d1 = 5T1 to ensure full recovery, pH 4-9
(±0.03) and 25 °C; degassed with N2 for 2 mins.
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2.4.2 Synthetic Procedures

2-((1,4,7,10-tetraazacyclododecan-1-yl)methyl)-4-nitrophenol (2.6)
Tri-formyl cyclen 2.3 (400 mg, 1.56 mmol) and NaHCO3 (262 mg, 3.12 mmol)
suspended in CH3CN (15 mL) were stirred for 5 mins at rt upon which 2-hydroxy-5nitrobenzyl bromide 2.4 (724 mg, 3.12 mmol) in CH3CN (5 mL) was added dropwise.
Stirring was continued for 18 h at 40oC. The mixture was concentrated and carried
forward to the next step as is. Crude product 2.5 was dissolved in 2M HCl (8 mL).
Stirring was continued for 18 h at 60oC. The mixture was concentrated then precipitated
with ether. The title compound was obtained as a cream solid (323 mg, 64%). 1H NMR
(400 MHz, D2O) δ 8.19-8.15 (2H, m), 7.04 (1H, d, J = 9Hz), 3.72 (2H, s), 3.12 (8H,
broad s), 3.06 (4H, broad s), 2.99 (2H, broad s), 2.84 (2H, broad s). ESI-TOF m/z calcd
for C15H26N5O3 (M +H)+, calculated 324.2036, found 324.2035.

Triethyl

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.8) Starting material 2.6 (250 mg, 0.773
mmol) and NaHCO3 (260 mg, 3.092 mmol) were suspended in CH3CN (8 mL) and
stirred for 5 mins at rt upon which ethyl (2-chloroacetyl)glycinate 2.7 (555 mg, 3.092
mmol) dissolved in CH3CN (2 mL) was added dropwise. Stirring was continued for 36 h
at 50oC. The mixture was filtered and the filtrate concentrated. The crude was purified by
column chromatography (silica gel) by eluting with 0-5% MeOH in CH2Cl2 to give the
product. The title compound was obtained as a yellow oil (367 mg, 63%). 1H NMR (400
MHz, CDCl3): δ 8.29-8.17 (3H, m), 8.07-8.04 (1H, dd, J = 9Hz), 7.92 (1H, d, J = 2Hz),
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6.49 (1H, s), 4.12 (2H, q, J = 7Hz), 4.05-3.94 (6H, m), 3.81 (4H, broad s), 3.4-2.77 (16H,
m), 2.67 (8H, broad s), 1.25 (3H, t, J = 7Hz), 1.15 (6H, t, J = 7Hz). 13C NMR (100 MHz,
CDCl3): δ 171.81, 170. 73, 169.64, 126.67, 125.85, 119.48, 117.33, 61.44, 59.72, 58.78,
57.69, 51.28, 49.43, 40.67, 13.93. ESI-TOF m/z calcd for C33H53N8O12 (M+H)+,
calculated 753.3783, found 753.3763.

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-nitrobenzyl)1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tris(acetyl))tris(azanediyl))triacetate (2.9)
Starting material 2.8 (300 mg, 0.399 mmol) was dissolved in 8 mL of 2.5 M NaOHMeOH (1:1) mixture and stirring continued for 18 h at rt. The mixture was concentrated
and brought to pH 6 by addition of 1M HCl. This was again concentrated and purified by
twice by size exclusion column chromatography (100% H2O) and the fractions
lyophilized to give the product. The title compound was obtained as a yellow solid (192
mg, 72 %).1H NMR (400 MHz, D2O) δ = 8.10 (1H, s), 7.97 (1H, d, J = 9Hz), 6.40 (1H,
d), 3.80-3.55 (7H, m), 3.22-2.40 (23H, m). ESI-TOF m/z calcd for C27H41N8O12 (M+H)+,
calculated 669.2844, found 669.2822.

General procedure for metalation. Starting material 2.9 was dissolved in H2O (1 mL)
then the appropriate lanthanide chloride salts added. The pH was adjusted to 6 and the
reaction mixture heated to 35oC - 40oC and left for overnight. The mixture was
concentrated, purified by size exclusion chromatography (100% H2O) and the fractions
lyophilized.
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Gadolinium(III)

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.10) Starting material 2.9 (31 mg, 0.046
mmol) and GdCl3.6H2O (17 mg, 0.046 mmol). The title compound was obtained as a pale
yellow solid (19 mg, 51%). ESI-TOF m/z calcd for C27H38 N8O12Gd (M-2H)+, calculated
824.1850, found 824.1888.

Europium(III)

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.11) Starting material 2.9 (25 mg, 0.037
mmol) and EuCl3.6H2O (14 mg, 0.037 mmol). The title compound was obtained as a pale
yellow solid (16 mg, 53%). ESI-TOF m/z calcd for C27H38 N8O12Eu (M-2H)+, calculated
819.1822, found 819.1858.

Thulium(III)

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.12) Starting material 2.9 (30 mg, 0.045
mmol) and TmCl3.7H2O (18 mg, 0.045 mmol). The title compound was obtained as a
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pale yellow solid (19 mg, 51%). ESI-TOF m/z calcd for C27H38 N8O12Tm (M-2H)+,
calculated 835.1951, found 835.1949.

Terbium(III)

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.13) Starting material 2.9 (30 mg, 0.045
mmol) and TbCl3.7H2O (25 mg, 0.068 mmol). The title compound was obtained as a pale
yellow solid (33 mg, 89%). ESI-TOF m/z calcd for C27H38 N8O12Tb (M-2H)+, calculated
825.1863, found 825.1862.

Ytterbium(III)

2,2',2''-((2,2',2''-(10-(2-hydroxy-5-

nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)tris(acetyl))tris(azanediyl))triacetate (2.14) Starting material 2.9 (30 mg, 0. 045
mmol) and YbCl3.6H2O (49 mg, 0.127 mmol). The title compound was obtained as a pale
yellow solid (72mg, 68 %). ESI-TOF m/z calcd for C27H38 N8O12Yb (M-2H)+, calculated
840.1998, found 840.2010.
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2.4.3 Spectra
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S 2.3: 13C-NMR Spectrum of 2.8
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Chapter 3
3

Transition Metal Complexes of Semi-rigidified and FullyRigidified DOTAM

3.1 Introduction
T1 contrast agents are more often than not, either small macrocyclic complexes like Gd3+DOTA, or linear metal complexes such as Gadodiamide (Figure 3.1). The molecular
structure of any MRI contrast agent will influence its thermodynamic and kinetic
stability, the magnitude of the induced shifts (in the case of PARACEST agents) and
even its spectroscopic properties.1 The acyclic complexes have higher flexibilities, which
may facilitate faster water exchange, an important criterion for a good T1 agent.1

Figure 3.1: Chemical structures of some ligands and complexes discussed in this
work.

As previously mentioned in Chapter 1, it is becoming more widespread for PARACEST
agents to be designed based on the macrocyclic DOTAM (Figure 3.1). Substituting the
acetate arms of DOTA with amide arms provides a reduced electron density at the metal
center that in turn leads to the slower exchange of the exchangeable protons of -NH, -OH
and a metal bound water. This slow exchange is a requirement for a CEST signal to be
produced.1
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DOTA and its associated structures such as DOTAM, offer higher preorganization,
symmetry and rigidity, as compared to conventional acyclic ligands. Once chelation with
a metal occurs, these properties subsequently influence the coordination geometries of the
macrocycles. DOTA forms very stable lanthanide chelates by adopting either one of two
conformations: square anti-prismatic (SAP, more stable) or a twisted square-antiprismatic
(TSAP, less stable) (Figure 3.2). The coordination geometry is dictated by the
configuration of the substituents on the backbone of the ring as well as the pendant arms.
Hence, the two isomers can be differentiated by their respective angles between the NLn-N and O-Ln-O planes (α). If the angle α, between the plane of the coordinating
nitrogens of the backbone and the oxygens of the pendant arms is about 39o, that
indicates the SAP geometry. On the other hand, an α of 25o indicates the TSAP
geometry.2 Larger lanthanide ions (earlier in the period of the periodic table) that are
coordinated to DOTA, tend to preferentially form the TSAP isomer while the smaller
lanthanides (later in the period), prefer the SAP isomer.3
O
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Figure 3.2: Schematic representations of the possible isomeric geometries of Ln3+DOTA.

It has been shown that the water exchange rate in the SAP isomer of DOTAM is about 50
times slower than that of the TSAP isomer.3, 4 In the TSAP isomer, the bound water is
further away from the metal centre and this facilitates a faster exchange with the
surrounding water molecules.2 It has also been demonstrated that the coordination
geometry in DOTAM ligands having bulky amide substituents, normally led to the
formation of the SAP isomer.5 However, the coordination geometry of these types of
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complexes was also found be affected by the nature of the solvent.5 Considering that slow
exchange is desired for CEST, using DOTAM ligands that are prone to form the SAP
isomer should ideally produce good PARACEST agents.
Potentially, another way to form the SAP isomer over the TSAP isomer is by means of
rigidification. Rigidification may be achieved by placing groups on either the backbone
of the macrocyclic ring, the alpha position of the pendant arms, or in both positions
concurrently. Additionally, rigidification increases the kinetic inertness of the metal
complexes.6 This is likely due to the more compact macrocyclic cage that prevents the
nitrogen atoms from being protonated, thus leading to dissociation of the metal from the
ligand.6
Interest in the modulation of the CEST signal due to the amide proton, directed the
research to determine the effect the rigidity of DOTAM-like structures would have on
amide CEST generation. This effect has not been studied in detail for DOTAM-like
structures. Nonetheless, it has been reported that the TSAP isomer of DOTA and
DOTAM ligands, which have been rigidified by one substituent on the backbone of the
ring or on each of the pendant arms, have a faster exchange of bound water.3, 7, 8 It was
anticipated that by rigidifying the DOTAM backbone, the preferred SAP conformation
for CEST would be “locked in”. Taking into account that the amide arms inherently
allow for slow exchange of the amide protons, it was hypothesized that an even higher
CEST effect should be generated by rigidification of the macrocycle, compared to that
due solely to the amide protons.
It was decided, that the structures to be investigated as PARACEST agents would have
the DOTAM core structure but be rigidified through substitution of at least one
cyclohexyl group on the macrocyclic ring. The cyclohexyl rings should additionally
increase the hydrophobicity of the complexes. Hence, for in vivo applications, there may
be favourable uptake into specific organs of the body.6 Optimistically, this would provide
an opportunity to view these organs by CEST imaging. However, one should bear in the
mind that if the agent is too hydrophobic, it might spend a longer time in these organs
than is medically safe. Additionally, due to the presence of the amide protons of the
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pendant arms, these agents may be pH responsive probes, hopefully within the
biologically relevant pH range (pH 7.35-7.45).

3.2 Results and Discussion
3.2.1 Synthesis
Figure 3.3 shows the initial target fully-rigidified 3.1a and semi-rigidified 3.2a
complexes for this study. The route to achieve these complexes was to follow similar
procedures published by Desreux et al., with the most important step being a "crab-like"
condensation between a bischloroacetamide and a diamine.9 However, due to the
difficulties faced during this crucial step, we modified the target ligands. It is noteworthy
to mention, that previous work done on complexes similar to those shown in Figure 3.3,
was within the context of conventional T1 MRI agents and as such had the acetate arms of
the DOTA core structure.9

Figure 3.3: Initial target complexes and their intermediate structures.
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Synthesis of fully-rigidified complexes
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Scheme 3.1: Synthetic route to new target fully-rigidified complexes.

Scheme 3.1 shows the synthetic route taken to achieve the new target fully-rigidified
ligand 3.9. Initially, the free diamine of 3.3 and chloroacetyl chloride was used to form
the bischloroacetamide analogue of 3.4 according to literature procedures.10, 11 However,
that product was not isolated in high yield. Several methods were attempted in order to
increase the yield of the bischloro analogue of 3.4. These included varying the solvents
(dioxane, CH2Cl2, toluene), reaction times (6 - 24 hrs) and temperature (-20oC to rt).
Additionally, both organic and inorganic bases were employed and the equivalents of the
electrophile chloroacetyl chloride (2.2 - 5 eq) were adjusted. Furthermore, oxalyl chloride
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as well as to bromoacteyl bromide were used to increase the strength of the electrophile.
Unfortunately, none of these changes improved the yields of the desired bisacetamide.
We opted to use the diamine salt 3.3 that would allow for easier handling. However, it
was insoluble in the solvents that were being used for the reaction and this likely had an
effect on the low yields that were obtained. As a result, a Schotten-Baumann reaction
using two phases of solvents was done following literature procedure.12 These reaction
conditions addressed the solubility issue. Using bromoacteyl bromide as the electrophile,
the reaction proceeded very well and the product 3.4 was easily isolated in excellent
yield.
Upon obtaining 3.4, the "crab-like" condensation with the diamine salt 3.3 was
performed. The reaction was monitored by UPLC and two products were observed in the
chromatogram. One product corresponded to the fully-rigidified intermediate 3.1b shown
in Figure 3.3. The other product was the major one and had a mass with a higher
molecular weight. The difference in mass between the two products indicated that the
larger molecular weight product had an additional bisacetamide group. The identical
reaction reported in the literature 9 made no mention of this larger by-product, although a
yield of only 23% was reported for the smaller molecular weight product.
Several things were done in order to improve the yield of 3.1b. These included varying
the type of base and its equivalents (organic and inorganic; 2-10 eq), solvents (CH3CN,
anhydrous EtOH, DMF), reaction times (up to 4 days) and temperatures (rt to 80oC).
These changes did not improve the yield of the desired product 3.1b. Using varying
equivalents of the bisbromo- or bischloroacetamide electrophile, as well as creating an in
situ bisiodoacetamide also proved unsuccessful. The templating agent LiBr, was also
used according to a procedure by Sharma et al.13 Moderate to excellent yields were
reported in the formation of macrocycles, which had been semi-rigidified with a benzene
ring. Using templating agents is a well-established strategy for forming macrocycles such
as crown ethers.13
Due to the afore-mentioned problems, it was decided that the diamine salt 3.3 be
protected using TsCl. This protection step was initially challenging, giving low yields
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after following reported procedures.10,

11

It was decided that a Schotten-Baumann

reaction, similar to that followed for the synthesizing the bisbromoactemide 3.4, should
be used to improve the yield. This approach was successful giving the ditosylated
diamine analogue of 3.3 in excellent yield.
The cyclization reaction between the ditosylated product and 3.4 was attempted.
Monitoring the reaction by UPLC showed the desired smaller molecular weight product
as the major product, in addition to a by-product with a larger molecular weight. The
mass difference between the two products corresponded to an additional ditosylated
diamine. Initial attempts at separation and purification of this mixture were unsuccessful
due to solubility issues. However, a solvent system of 10-30% acetone in CH2Cl2 was
attempted and the desired and undesired products were isolated in low yields of roughly
equal amounts.
The removal of the Ts protecting groups proved problematic. LiAlH4 is a good reducing
agents for amides and can also be used to remove Ts groups. As such, it was hoped that
this reagent would allow for a simultaneous reduction and detosylation as demonstrated
previously.14 In this instance, neither reaction worked, with only the starting material
being present even after heating to 50oC for 2 days. Detosylation was also attempted
fruitlessly with 0.1M SmI2 in THF,15 heating at 80oC in 32% HBr in acetic acid

16

and

using a Ti(OiPr)4/Me3SiCl/Mg combination.17 Refluxing in concentrated H2SO4 only
partially worked, even after heating up to 5 days at 110oC. The UPLC chromatogram for
that reaction showed a mixture containing starting material as well as partially and fully
deprotected compounds. Although the mixture was separated, there were discrepancies
observed during characterization of the desired product. The HR-ESI-MS showed the loss
of the tosyl groups but the 1H-NMR showed aromatic peaks in the spectrum. Attempts to
further purify the compound were unsuccessful.
The difficulty associated with the removal of Ts groups has also been earlier
demonstrated.18 In light of the previous results indicating the need for a protecting group
to increase the yield of the initial target intermediate, other protecting groups were
investigated. The Ns group was used but the results were the same as that of the Ts
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groups during both the cyclization and deprotection steps. The diamine salt 3.3 was
protected with Boc groups but no reaction occurred during cyclization with the
bisbromoacetamide. It was based on these exhaustive attempts to improve the yield of the
initial fully-rigidified intermediate 3.1b, that we modified our target complexes to those
based on compound 3.9 (Scheme 3.1).
Following cyclization of 3.3 and 3.4, the reaction mixture was purified by column
chromatography and product 3.5 was obtained in 31% yield. Reduction of the amide
groups of 3.5 was done using 1M BH3 in THF and the desired compound 3.6 was isolated
in good yield. Peralkylation of 3.6 with ethyl (2-chloroacetyl)glycinate 3.7, followed by
saponification, afforded the fully-rigidified ligand 3.9 in a moderate yield of 54% after
two steps.
Metalations of ligand 3.9 with lanthanides of varying sizes (Eu3+, Tm3+, Yb3+, Nd3+,
Gd3+) were carried out as reported9 but were unsuccessful. The conditions tried included
varying the equivalents of the lanthanide salts, solvents, reaction times and temperatures.
It was at this point speculated that the inner cavity of the fully-rigidified ligand 3.9 was
too small to accommodate a lanthanide. The ionic radii of the lanthanides range from
1.143 Å for Ce3+ to 0.985 Å for Yb3+.19 It is likely that the chelate cavity is much smaller
than this range. Within the context of PARACEST, the metals most commonly used are
lanthanides but more recently, there have been reports of transition metals such as cobalt
(Co2+),20, 21 nickel (Ni2+)22 and iron (Fe2+),23-26 being used to generate CEST due to the
amide protons.27 As such, metalation with some of the smaller transition metals (Fe2+,
Co2+, Ni2+, Cu2+, Zn2+ and Ga3+) was performed. The metalation of ligand 3.9 was
partially successful, giving complexes 3.10 - 3.13 in moderate to good yields. However,
no metalation occurred with Fe2+ and Ga3+. The ionic radii of these two metals are 0.62 Å
and 0.92 Å for Ga3+ and Fe2+, respectively. 19 In regards to Co2+, Ni2+, Cu2+ and Zn2+ that
formed complexes, the ionic radii ranged from 0.69 Å for Ni2+ to 0.90 Å for both Co2+
and Zn2+. It may therefore be inferred that the chelate cavity for the fully-rigidified ligand
is greater than 0.62 Å but less than 0.92 Å. The preference of this ligand for transition
metals over lanthanides showed the ability of the fully-rigidified ligand to discriminate
based on size. This is perhaps due to the very rigid nature of the ligand and the associated
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distortion it causes to the cavity. Additionally, the presence of the acetamide-glycinate
arms may cause steric crowding which leads to further discrimination against the larger
lanthanides. This may be confirmed or disproved by solid state analysis but
unfortunately, attempts to grow crystals of the complexes were not successful.
Synthesis of semi-rigidified complexes

Scheme 3.2: Synthetic route to new target semi-rigidified complexes.

As previously mentioned, the lack of success in the lanthanide metalations of the fullyrigidified ligand 3.9 could be as a result of the very rigid nature of the ligand. For
comparison purposes, the synthesis of the semi-rigidified counterpart that contained only
one cyclohexyl ring was subsequently attempted. A similar synthetic pathway to that of
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the fully-rigidified complex was followed starting with the bisbromoacetamide formation
of ethylenediamine (Scheme 3.2). It was hoped that the reduction in rigidity would also
lead to the formation of complexes of 3.2 shown in Figure 3.3. Unfortunately, similar
problems as described earlier for the initial fully-rigidified complexes of 3.1 were faced.
Hence, target 3.2 was altered to that based on the larger macrocycle 3.19.
Using X-ray crystallography, characterization of the product 3.16 of the "crab-like"
condensation reaction was possible. Crystals of 3.16 were obtained by dissolving the
compound in CHCl3 and layering with petroleum ether. After a series of similar steps
earlier described, the semi-rigidified ligand 3.19 was obtained (Scheme 3.2).
The attempts to metalate the semi-rigidified ligand 3.19 with lanthanides also failed. In
retrospect, it may be possible that the lanthanides partially coordinate to the fullyrigidified and semi-rigidified ligands at some point but falls out due to the distortion by
the cyclohexyl groups appended to the backbone. Metalation with the same transition
metals used for the fully-rigidified ligands was more successful and complexes 3.20 3.24 were obtained in good to excellent yields. Although the Ga3+ reaction was still
unsuccessful, the metalation with Fe2+ worked. Based on this and previous observations,
the fully-rigidified ligand is more selective than the semi-rigidified ligand. The reduced
selectivity of the semi-rigidified ligand is likely due to the removal of a cyclohexyl
group. Similar attempts to grow crystals for solid state analysis were not successful.

3.2.2 Crystal Structure
The crystal structure data of 3.16 is summarized in Table 3.1. The structure of 3.16 as
shown in Figure 3.4a consists of three rings, the common points holding them together
being two tertiary nitrogens, N1 and N4. This gives the molecule a "Y-like" appearance.
One can image the cyclohexyl ring being the vertical stem and the other two ninemembered rings being the arms (Figure 3.4b). The cyclohexyl ring is not distorted and
remains in its favourable chair conformation. The starting diamine salt 3.3 had an
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absolute configuration of R, R-(+) (corresponding to C13 and C14). This configuration
remained unchanged given that C13 and C14 are not sites of reactivity.

(a)

(b)

Figure 3.4: (a) ORTEP drawing of 3.16 showing naming and numbering scheme.
Ellipsoids are at the 50% probability level and hydrogen atoms were drawn with
arbitrary radii for clarity. Water of hydration omitted for clarity. (b) Ball and stick
representation of 3.16, showing its Y-like shape.

The interesting feature of ligand 3.16 is the tertiary N1 and N4 that originated from the
cyclohexyl diamine. The expected bond length for each N-C single bond in tertiary
amines is 1.469 Å.28 The three bonds to N1 consisted of two bonds (new bond N1-C12
and original bond N1-C13) that were close to the expected value of 1.469 Å (average
length = 1.465 Å). The other new bond N1-C7 was much shorter by 0.021 Å (Table 3.2).
On the other hand, two of the three bonds to N4 consisted of the shorter new N4-C7 bond
(∆Å = 0.009) and the original N4-C14 bond (∆Å = 0.01) being the longest. Surprisingly,
the bond length of N4-C14 is identical to the N-C bond of endo δ-lactams of the type C1N(-C1)-C=O (1.479 Å).28 The third bond N4-C6 (new) was identical to the expected
value of 1.469 Å. The difference in bond length between the original bonds N1-C13 and
N4-C14 may be due to the difference in the spatial orientation of these bonds. Each bond
is pointing in opposite directions and the corresponding nitrogen atoms may require
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different degrees of lengthening in order to each form two additional N-C bonds.
Considering that the N4-C14 bond was the longest, this likely had to undergo the most
change.
Table 3.1: Crystal data and structure refinements for 3.16.
Formula
C18H32N6O5
Formula Weight (g/mol)
412.49
Crystal Dimensions (mm )
0.325 × 0.320 × 0.122
Crystal Color and Habit
colourless prism
Crystal System
orthorhombic
Space Group
P 21 2 1 2 1
Temperature, K
110
Unit cell dimensions
a, Å
9.504(2)
b, Å
14.103(3)
c, Å
14.726(4)
α,°
90
β,°
90
γ,°
90
V, Å3
1973.9(8)
Z
4
F(000)
888
ρ (g/cm)
1.388
λ, Å, (MoKa)
0.71073
μ, (cm-1)
0.103
Number of reflections to determine final unit cell
9608
Number of reflections measured
174049
Unique reflections measured
13523
R1
0.0353
0.0871
wR2
R1 (all data)
0.0449
wR2 (all data)
0.0916
GOF
1.066
Min & Max peak heights on final DF Map (e-/Å)
-0.205, 0.473

Unpredictably, only one bond angle (C7-N4-C6) involving either of the tertiary N1 or N4
corresponded to a tetrahedral geometry for sp3 nitrogens (Table 3.3). The other bond
angles are greater than 109.5o and range from 113o - 117o, thus falling between that of an
sp3 (109.5o) and sp2 (120o) nitrogen. It is possible that while in solution state, nitrogen
inversion occurred, leading to the interconversion from tetrahedral to trigonal planar and
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back to tetrahedral geometry. This interconversion may be possible since the ring systems
involving N1 and N4 are large ring systems with less strain. However, upon forming
crystals, a hybrid developed, thereby leading to bond angles between the two geometries.
Table 3.2: Selected bond lengths (Å) for 3.16.
N1-C1
N1-C13
N1-C12
C6-N4
N4-C7
N4-C14

1.4482(10)
1.4646(10)
1.4647(10)
1.4680(10)
1.4602(10)
1.4788(10)

Table 3.3: Selected bond angles (o) for 3.16.
C1-N1-C13
C1-N1-C12
C13-N1-C12
N1-C1-C2
N1-C1-H1A
N1-C1-H1B
N4-C6-C5
N4-C6-H6A
N4-C6-H6B
C7-N4-C6
C7-N4-C14
C6-N4-C14

117.07(7)
116.77(7)
114.33(6)
112.67(7)
109.6(12)
111.4(9)
112.68(6)
111.7(11)
107.1(9)
108.85(6)
113.84(6)
113.82(6)

N4-C7-C8
N4-C7-H7A
N4-C7-H7B
N1-C12-C11
N1-C12-H12A
N1-C12-H12B
N1-C13-C18
N1-C13-C14
N1-C13-H13
N4-C14-C15
N4-C14-C13
N4-C14-H14

113.11(6)
113.1(9)
108.3(10)
108.55(6)
113.6(11)
111.2(10)
114.15(7)
113.98(6)
103.9(9)
113.18(6)
112.30(6)
104.6(9)

3.2.3 Magnetic Properties
Magnetic moments
The magnetic moments for the Co2+ (3.11) and Ni2+ (3.12) fully-rigidified complexes
were determined and found to be 3.93 and 2.80 μB, respectively. These observations are
in agreement with that of high spin Co2+ and Ni2+ complexes.29 These values indicated
that the coordination number (CN) for both complexes is six but due to distortion, the
geometry is pseudo-octahedral rather than octahedral.29
The magnetic moments for the Co2+ (3.21) and Ni2+ (3.22) semi-rigidified complexes
were 4.81 and 3.52 μB, respectively, which are in agreement with that of high spin Co2+
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and Ni2+complexes.29 The value reported for the Ni2+ complex (3.22) indicated that the
coordination geometry is pseudo-tetrahedral rather than tetrahedral due to distortion (CN
= 4).29 Similarly, distortion of the Co2+ complex (3.21), led to a pseudo-octahedral
geometry (CN = 6).29
A value of 2.49 μB for Fe2+ (3.23) indicated a low spin compound which could be either
Fe2+ or Fe3+, thus this value is considered to be anomalous.29 However, there are a few
things that should be considered in order to establish a reasonable oxidation state of iron
in this complex. Firstly, if a fully-rigidified complex containing iron had been made, the
oxidation state of iron and thus the ionic radii would be the same in both types of
rigidified complexes. Secondly, octahedral Fe3+ has a smaller ionic radius (low spin =
0.55 Å and high spin = 0.645 Å) than Fe2+, Ni2+ and Co2+ and metalation with iron did
not occur with the fully-rigidified macrocycle 3.9. Thirdly, the ionic radius of high spin
Fe3+ is similar to that of Ga3+ (0.620 Å) which did not metalate either the semi-rigidified
or fully-rigidified ligands, meaning that these metals are too small for the cavities of the
ligands. Hence, it can be inferred that iron in the semi-rigidified complex must be the
larger low spin Fe2+, which was too large for the fully-rigidified ligand.
CEST studies
CEST data was collected at pH 6, 7 and 8 at T = 25oC and 37oC for the Co2+ and Ni2+
fully-rigidified complexes 3.11 and 3.12 as well as the Co2+, Ni2+ and Fe2+semi-rigidified
complexes 3.21, 3.22 and 3.23 (10 mM, 9:1 D2O/H2O). Unfortunately, no CEST signals
were observed. Similarly, no signals were observed when CEST experiments of the
complexes at 20 mM in pH 7 phosphate buffer (0.02 M) at 37oC were performed.
The most likely reason for the absence of an amide CEST signal is that the exchange rate
of the amide protons may be outside the required regime for a CEST effect to be
observed. This faster exchange rate could be due to the very rigid nature of the ligands,
considering that Co2+, Ni2+ and Fe2+ in simpler ligands such as DOTAM have shown
amide CEST signals.21, 22 While the coordination geometry of the transition metal in the
complexes may also negatively impact the CEST signal generation, the exact geometries
are unknown. The deviation from the lanthanide-containing DOTA-like complexes, as
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represented in the original target complex structures (Figure 3.1), means that the
definition of SAP and TSAP coordination geometries (nine-coordinate with respect to
lanthanide ions) cannot be used in context with these highly rigidified macrocycles
containing transition metals. Based on the results of the magnetic moments of the
transition metals, their geometries may be tetrahedral (four-coordinate) and or octahedral
(six-coordinate), with some distortions. The transition metals used to form these
complexes are therefore coordinatively saturated and unlikely to form three additional
coordinating bonds. Therefore, it cannot be reasonably concluded that the lack of a CEST
signal is also due to the formation of the unwanted TSAP isomer, which in DOTA-based
complexes, have faster exchange rates of exchangeable protons.
Relaxivity studies
The relaxivity properties of the Co2+ (3.11) and Ni2+ (3.12) fully-rigidified complexes as
well as the Co2+ (3.21), Ni2+ (3.22) and Fe2+ (3.23) semi-rigidified complexes were
determined and the results are shown in the Table 3.4. The low r1 values of the complexes
are comparable to those reported for macrocyclic complexes involving these metals. 21, 22,
24

Based on these values, it is likely that there is no water molecule bound to the metal

center. The variation in r1 values of the complexes were not based on the type of ligands,
but rather on the type of metal, with the Ni2+ complexes having the highest values.
Table 3.4: r1 and r2 values of agents 3.11 - 3.12 and 3.21 - 3.23 at 37°C and pH 7.00 ±
0.03.

Fully-rigidified
Semi-rigidified

Mn+
Co2+ (3.11)
Ni2+ (3.12)
Co2+ (3.21)
Ni2+ (3.22)
Fe2+ (3.23)

r1 (mM-1s-1)
0.052
0.268
0.081
0.246
0.097

r2 (mM-1s-1)
0.262
0.345
0.463
0.365
3.17

r2/r1
5.04
0.507
5.72
1.48
32.7

On the other hand, while there was no significant variation in the r2 values of Ni2+
complexes 3.12 and 3.22, a difference was seen in the values for the Co2+ complexes 3.11
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and 3.21, with the semi-rigidified complex having an r2 value that is more than one and a
half times that of the fully-rigidified complex. With the exception of the lone Fe2+
complex, these r2 values were comparable to those previously reported. 21, 22
The r2 value of 3.17 mM-1s-1 for the Fe2+ complex 3.23 was the highest of all the
complexes and higher than that reported previously for other Fe2+ macrocyclic
complexes.24 Nevertheless, in comparison to superparamagnetic iron oxide nanoparticles
(SPIONs) that have r2 values greater than 70 mM-1s-1 at 60 MHz,30 the r2 value of 3.17
mM-1s-1 for the Fe2+ complex 3.23 is obviously much lower at 400 MHz.
The r2/r1 ratio for both Co2+ complexes 3.11 and 3.21 are similar, while that of the semirigidified Ni2+ complex 3.22 is almost three -fold higher than the fully-rigidified Ni2+
complex 3.12. The r2/r1 ratio of Fe2+complex 3.23 is the highest of all the complexes
described here as well as that of reported for various SPIONs such as TMAOH
(tetramethylammonium hydroxide) SPION and Resovist®.30 This recorded high value
shows the preference of negative contrast enhancement (darkening effect), thus indicating
that the interference from the T1 effect (lightening effect) is small.30

3.2.4 UV Studies
Stability studies
Stability studies of the complexes (1 mM in H2O) at pH 2-11 were carried out
spectrophotometrically in order to further characterize the complexes made. At pH 7, the
λmax for the fully-rigidified Cu2+ complex 3.10 (Figure 3.5a) and Co2+ complex 3.11
(Figure 3.5c) was 584 nm and 525 nm, respectively. Although the Ni2+ complex 3.12 was
a dark green solid, in solution it was almost colourless, making it difficult to obtain its
λmax. No stability studies were done with the Zn2+ complex 3.13 since it was naturally a
cream -coloured compound.
The absorbances of complexes 3.10 and 3.11 at acidic pH were low, indicating possible
demetalation. However, at basic pH a hyperchromic shift was observed, possibly
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indicating increased stability. The solutions of 3.10 and 3.11 at pH 2 and 11 were left
undisturbed for a week at room temperature and their UV absorbance re-measured. The
Cu2+ complex 3.10 (Figure 3.5b) and Co2+ complex 3.11 (Figure 3.5d) showed no
significant difference in absorbances at lower pH, but there was a slight increase in
absorbance for the complexes at pH 11.
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Figure 3.5: Absorption spectra of fully-rigidified complexes Cu2+ 3.10 (a) and (b)
and Co2+ 3.11 (c) and (d). Figures (a) and (c) are at pH 2 - 11 and (b) and (d) are at
pH 2 and 11 taken 1 week later. Each complex concentration was 1 mM in H2O at
25oC.

61

1.2

(a)

0.6
0.4
0.2
0.0

pH 2
pH 2_1 wk
pH 7
pH 11
pH 11_1 wk

1.0

Absorbance (a.u.)

Absorbance (a.u.)

1.0
0.8

1.2

pH 2
pH 3
pH 4
pH 5
pH 6
pH 7
pH 8
pH 9
pH 10
pH 11

(b)

0.8
0.6
0.4
0.2

400

500

600

700

800

0.0

400

λ (nm)

500

600

700

800

λ (nm)

Figure 3.6: Absorption spectra of semi-rigidified complex Cu2+ 3.20 (a) at pH 2 - 11
and (b) pH 2 and 11 taken 1 week later Each complex concentration was 1 mM in
H2O at 25oC.

Similar stability studies at pH 2-11 were carried out for the semi-rigidified complexes
3.20, 3.21 and 3.23. Likewise, no stability studies were done with the Ni2+ 3.22 and Zn2+
3.24 complexes for the reasons mentioned earlier. At pH 7, the λmax in H2O occurred at
637 nm for the Cu2+ complex 3.20 (Figure 3.6a), 525 nm for the Co2+ complex 3.21
(Figure 3.7a) and 473 nm for the Fe2+ complex 3.23 (Figure 3.7c). The Cu2+ complex
3.20 seemed to be more stable at pH 6 or greater since a slight hyperchromic shift was
observed at those pH values. Both Co2+ 3.21 and the Fe2+ 3.23 complexes had their
highest absorbance at pH 7, indicating higher stability.
The absorbances at pH 2 and pH 11 were re-measured one week later during which the
solutions were left at room temperature. There was no difference in absorbance for the
Cu2+ complex 3.20 (Figure 3.6b) and only a slight difference in the absorption spectra of
the Co2+ complex 3.21 (Figure 3.7b) at those pH values. The Fe2+ complex 3.23 (Figure
3.7d) had a lower absorbance one week later at pH 2 but there was no difference in
absorbance of the pH 11 values.
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Figure 3.7: Absorption spectra of semi-rigidified complexes Co2+ 3.21 (a) and (b)
and Fe2+ 3.23 (c) and (d). Figures (a) and (c) are at pH 2 - 11 and (b) and (d) are at
pH 2 and 11 taken 1 week later. Each complex concentration was 1 mM in H2O at
25oC.

The aqua complexes of Cu2+, Fe2+, Co2+ and Ni2+ have weak absorbances occurring in the
near infrared region.31 This may account for the small absorbances due to d-d transitions,
seen in the aqueous solutions of the fully-rigidified and semi-rigidified complexes at 800
nm. That feature is comparable to that of Cu2+ complexes of tetraaza macrocycles such as
DOTA32 and DOTAM33. That feature is not restricted to DOTA or DOTAM. In Cu2+
polyaminocarboxylic acids such as ethylenediaminetetraacetic acid (EDTA), this has also
been observed.34 Although these complexes are more rigid in nature, it is not surprising
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that they possess similar absorption characteristics as that of the unrigidified
macrocycles, seeing that no additional chromophores were incorporated in the structures.
Ligand exchange studies

Figure 3.8: Ligands and complexes used in the ligand exchange study.

UV ligand exchange studies were attempted in order to determine the strength of binding
of the ligands 3.9 and 3.19 to the metals. The first choice was phenanthroline (Figure 3.8)
because it has a strong absorbance in both its free and complexed states. Figure 3.9a
shows that the Cu2+-phenanthroline complex had a λmax of 273 nm while the free ligand
had a λmax of 262 nm in 1:1 H2O/pH 7 phosphate buffer. The titration was carried out
using the semi-rigidified Cu2+complex 3.20. Regrettably, there was an overlap of the
peaks at 273 nm and 262 nm, which made it difficult to estimate how much Cu2+ was
actually being released from the semi-rigidified ligand and being bound by
phenanthroline. Additionally, with less than 0.5 μM of phenanthroline added, there was
shift in λmax from 273 nm to 262 nm.
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Figure 3.9: Titration absorption spectra at 25oC of semi-rigidified complexes (a)
Cu2+ complex 3.20 (10 μM in 1 : 1 pH 7 (0.02 M) phosphate buffer/H2O) with
phenanthroline (500 μM in 10 μM Cu2+ complex 3.20 solution) and (b) Zn2+ complex
3.24 (10 μM in 1 : 1 pH 7 (0.02 M) phosphate buffer/H2O) with Zincon (500 μM in
10 μM Zn2+ complex 3.24 solution).
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The second choice of ligand for the afore-mentioned purpose was Zincon (Figure 3.8).
Ligand exchange experiments were carried out with Zincon and the semi-rigidified Zn2+
complex 3.24. Zincon binds strongly to Zn2+ (log β = 4.19, Kd = 64.44 μM).35 The
complex had a λmax at 600 nm while the free Zincon had its λmax at 470 nm in 1:1 pH 7
phosphate buffer/H2O (Figure 3.9b). The λmax of the Zn2+-Zincon complex and the free
Zincon has been observed at 620 and 488 nm, respectively, in borate buffer.35 However,
attempts to derive a Kd for complex 3.24 were unsuccessful, even although ∆λmax was
130 nm. Addition of up to 25 μM addition of Zincon (2.5X), caused both peak
absorbances at 470 and 600 nm to increase simultaneously, which is not an ideal
response. The reason for the increase in absorbances for both peaks was not investigated.
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Figure 3.10: Titration absorption spectra of Cu2+-Zincon complex (10 μM in 1 : 1
pH 8 (0.02 M) phosphate buffer/H2O) with fully-rigidified ligand (500 μM in 10 μM
Cu2+-Zincon complex solution) at 25oC.

The Cu2+-Zincon complex (Figure 3.8) was titrated with the fully-rigidified ligand 3.9.
The absorbance was measured for up to 95 μM of the ligand. As can be seen in Figure
3.10, there is no absorbance peak corresponding to the free Zincon. This reinforces that
the Cu2+-Zincon complex is a stable one (log β = 4.39, Kd = 40.01 μM).35 Heating at 60oC
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for overnight did not lead to formation of the Cu2+-fully-rigidified complex 3.10. The
negative absorbances observed at longer wavelengths when the concentration of fullyrigidified ligand was increased, may be attributed to the formation of aggregates.
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Figure 3.11: Absorption spectra of ligand exchange experiment with (a) Cu2+-DOTA
and Zincon at Cu2+-DOTA complex (10 μM in 1 : 1 pH 8 (0.02 M) phosphate
buffer/H2O) with Zincon (500 μM in 10 μM Cu2+-DOTA complex solution) at 25oC
and (b) Same solution at 60oC, four days later.
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The Cu2+-DOTA complex (log β = 22.25)36 was similarly titrated with Zincon. The UV
spectrum showed that no exchange occurred between the two as evidenced by the
absorption at ~488 nm which correlates to free Zincon (Figure 3.11a). The formation of
the Cu2+-Zincon complex was completed only upon overnight heating of the mixture at
60oC (Figure 3.11b).
Cu2+-DOTA complex and fully-rigidified ligand 3.9 were reacted together at room
temperature for overnight and the ligand exchange was monitored by UPLC. The
chromatogram showed that no exchange occurred (data not shown). A similar experiment
was done with the semi-rigidified ligand 3.19 giving the same results. Overnight heating
at 60oC also did not lead to the formation of either the Cu2+-fully-rigidified or semirigidified complexes.
Despite the fact that we were unable to quantitatively determine the stability of the fullyrigidified or semi-rigidified complexes, the afore-mentioned results of ligand exchange
indicates that the stability of these complexes is in the order of semi-rigidified ligand ≈
fully-rigidified ligand < Zincon < DOTA.

3.3 Conclusion
The synthesis of the initial target lanthanide complexes containing one and two
cyclohexyl rings appended to the backbone of DOTAM was met with several challenges.
Based on the low yields obtained for these initially desired ligands during cyclization, the
targets were modified to that of the very interesting and larger molecular weight byproducts. These semi-rigidified and fully-rigidified ligands possessed a most unusual
structure, as indicated by the X-ray crystal data of the intermediate semi-rigidified ligand.
This intermediate ligand had an additional bisacetamide group attached, thereby forming
a Y-shaped structure with two tertiary amines.
The new target ligands were observed to be selective towards the smaller transition
metals, rather than the desired larger lanthanides. Within these two types of ligands, the
fully-rigidified one was even more discriminating, since it did not form a complex with
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Fe2+. This observation of selectivity towards the transition metals indicated the smaller
cavity sizes of these ligands and this may be useful for scavenging metals of similar sizes.
The research showed that a CEST signal cannot be generated for the Ni2+, Co2+ and Fe2+
complexes under the different pH conditions and solvent mixtures used. At this time, it
may be simply inferred that the lack of a CEST signal was due to the rigid ligand design
that caused the exchange rate to fall outside of the desired regime for CEST. Considering
that these modified complexes are fused structures that have severely deviated from
DOTA-based ones, the definition of SAP and TSAP cannot be applied to these structures.
While coordination geometry may play a role, it cannot be construed that the absence of a
CEST signal is due to the exclusive formation the TSAP isomer, which is known to
possess a fast exchange rate for the metal bound water protons. In regards to T1 and T2
relaxivities, all the complexes gave low values but these were comparable to published
results. However, an exception was seen in the semi-rigidified Fe2+ complex, which had a
much higher T2 relaxivity.
The attempt to assess the selectivities of the ligands by performing exchange experiments
was met with difficulty. Nonetheless, it was possible to conclude qualitatively that both
types of rigidified ligands synthesized are weak chelators as compared to un-rigidified
ones such as DOTA.
The information gained here has indicated that the degree of rigidity in DOTAM-like
structures is important in binding of lanthanides as well as transition metals. More
rigidified structures led to better selectivity but the rigidity negatively affected the
generation of a CEST signal. It is still crucial to gain information regarding amide
exchange and accordingly, the amide CEST effect in a SAP isomer. Hence, towards that
goal, it may be necessary to reduce the level of rigidity in the target ligands. This may
provide an easier way of driving the formation of the preferred SAP isomer, which is a
promising advantage for good CEST signal generation.
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3.4 Supplemental Information
3.4.1 General Experimental
General synthetic details can be found in Appendix 1.
CEST and Relaxivity Experiments
CEST spectra were acquired on a 600 MHz vertical bore NMR spectrometer, using a 15
µT, 2 s continuous wave presaturation pulse at offset frequencies ranging from -110 to
110 ppm in steps of 1 ppm at a concentration of 10 mM in D2O/H2O (9:1) at pH 6.00 ±
0.03, 7.00 ± 0.03 and 8.00 ± 0.03; 37 °C and at a concentration of 20 mM in pH 7
phosphate buffer; 37 °C. T1 and T2 relaxation time constant measurements were made on
a 400 MHz vertical bore NMR spectrometer. T1 relaxation time constant measurements
were made for four different concentrations (1, 2, 4, 8 mM) of CA in H2O, using an
inversion recovery sequence (20 inversion times in the range of 0.1 s - 20 s) with a
minimum d1 = 5T1 to ensure full recovery, pH 7.00 ± 0.03 and 37 °C. T2 relaxation time
constant measurements were made for four different concentrations (1, 2, 4, 8 mM) of
CA in H2O, using a CPMG pulse sequence (15 inversion times in the range of 0.001 s - 7
s) with a minimum d1 = 5T1 to ensure full recovery, pH 7.00 ± 0.03 and 37 °C. VNMRJ®
software of the spectrometer automatically gave the T1 and T2 relaxation times from
which the corresponding relaxation rates were calculated. The relaxivities were then
determined from the slope of the linear regression fitting of the rates versus concentration
in Microsoft Excel.

3.4.2 Synthetic Procedures
General procedure for cyclization. A solution of bisbromoacetamide, K2CO3 and LiBr
were suspended in CH3CN and refluxed for 1 h and (1R,2R)-cyclohexane-1,2-diamine
tartrate in CH3CN was added and stirring was continued for 36 h. The reaction mixture
was filtered and the filtrate concentrated. The crude was purified by column
chromatography (silica gel; CH2Cl2/MeOH/NH4OH (90:10:1); charring with KMnO4).

70

(4aR,8R,11aR,15aR,19R,22aR,23R,24R)hexadecahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine6,10,17,21(7H,9H,18H,20H)-tetraone (3.5). Bisbromoacetamide (3.4) (0.889 g, 2.5
mmol), K2CO3 (2.07 g, 15 mmol) and LiBr (0.434 g, 5 mmol), (1R, 2R)-cyclohexane-1,
2-diamine tartrate 3.3 (0.661 g, 2.5 mmol) and CH3CN (vtot = 80 mL). Title compound
was obtained as a white solid (0.394 g, 31%). 1H NMR (400 MHz ,CDCl3): δ 8.67 (2H, d,
J = 10Hz), 6.70 (2H, d), 3.86-3.64 (4H, m), 3.51-3.44 (3H, m), 3.16-3.09 (5H, m), 2.462.40 (2H, m), 2.01-1.93 (4H, m), 1.82-1.66 (8H, m), 1.56-1.29 (10H, m), 1.13-1.05 (2H,
m).

13

C NMR (100 MHz, CDCl3): δ 174.51, 174.13, 66.74, 62.85, 56.12, 55.00, 53.55,

31.98, 25.53, 24.89, 24.75. ESI-TOF m/z calcd for C26H43N6O4 (M + H)+, calculated
503.3346, found 503.3350.

(1R,10R,10aR,14aR)-decahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine3,8,16,21(2H,9H)-tetraone (3.16). Bisbromoacetamide 3.15 (1.755 g, 5.81 mmol),
K2CO3 (3.9 g, 28.24 mmol) and LiBr (0.434 g, 5 mmol), (1R,2R)-cyclohexane-1,2diamine tartrate 3.3 (1.536 g, 5.81 mmol) and CH3CN (vtot = 170 mL). Recrystallization
from petroleum ether-CHCl3 gave the title compound as colourless crystals (0.529 g,
23%). 1H NMR (400 MHz ,CDCl3): δ 7.51 (2H, d) 7.17 (2H, d, J = 10Hz), 3.92 (2H,
broad s), 3.48 (2H, broad s), 3.37 (2H, broad s), 3.30-3.17 (4H, m), 2.90-2.65 (8H, m),
1.95 (2H, broad s), 1.68 (2H, broad s), 1.10 (2H, broad s), 0.97 (2H, broad s). 13C NMR
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(100 MHz, CDCl3): δ 174.07, 173.07, 61.12, 58.95, 53.59, 38.73, 37.74, 25.03, 23.97.
m.p. 247.3 - 250.1oC. ESI-TOF m/z calcd for C18H31N6O4 (M + H)+, calculated 395.2407,
found 395.2392.

General procedure for amide reduction. Macrocycle was dissolved in 1M BH3 in THF
and then refluxed for 3 days. After quenching with H2O, the mixture concentrated and
acidified with 6M HCl at 0oC then refluxed for overnight. Mixture was co-evaporated
with CH3CH2OH then dissolved in H2O and lyophilized. The brown sticky solid was
basified with NH4OH and extracted with CHCl3. The organic layers were collected, dried
over Na2SO4, concentrated and the residue co-evaporated with acetone. Product was then
carried forward to next step without further purification.

(4aR,8R,11aR,15aR,19R,22aR,23R,24R)tetracosahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine (3.6). Macrocycle
3.5 (0.335 g, 0.666 mmol), 1M BH3 in THF (30 mL), and 6M HCl (5 mL). The title
compound was obtained as a cream solid (0.242 g, 81%). 1H NMR (400 MHz ,CDCl3): δ
3.05 (2H, t, J = 14Hz), 2.72-2.65 (2H, m), 2.64-2.44 (10H, m), 2.40-2.28(4H, m), 2.282.15 (5H, m), 2.00 (2H, d, J = 13Hz), 1.95-1.85 (3H, m), 1.76-1.63 (8H, m), 1.33- 0.95
(14H, m).

13

C NMR (100 MHz, CDCl3): δ 61.41, 59.97, 57.10, 48.63, 47.35, 43.71,

40.76, 32.50, 29.76, 26.16, 25.36, 24.85. ESI-TOF m/z calcd for C26H51N6 (M + H)+,
calculated 447.4175, found 447.4156.
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(1R,10R,10aR,14aR)-tetradecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine

(3.17).

Macrocycle 3.16 (0.467 g, 1.184 mmol), 1M BH3 in THF (50 mL) and 6M HCl (9 mL).
The title compound was obtained as a cream solid (0.353 g, 88%). 1H NMR (400 MHz
,CDCl3): δ 3.07 (2H, t, J = 13Hz), 3.03-2.96 (2H, m), 2.78-2.47 (20H, m), 2.25 (2H, d),
1.94 (2H, d, J = 13Hz), 1.78-1.72 (2H, m), 1.30-0.99 (8H, m).

13

C NMR (100 MHz,

CDCl3): δ 61.43, 48.54, 46.23, 45.84, 45.14, 30.07, 29.62, 25.67, 24.44. ESI-TOF m/z
calcd for C18H39N6 (M + H)+, calculated 339.3236, found 339.3235.

General procedure for alkylation and deprotection. Starting material and K2CO3 were
suspended in CH3CN and ethyl (2-chloroacetyl)glycinate dissolved in CH3CN () was
added. The reaction mixture was heated to 60oC and left for 2 days. Reaction mixture was
filtered and the filtrate concentrated. The crude was the carried forward to the next step as
is.
Crude product was dissolved in MeOH/1M NaOH (1:1) and left stirring at rt for
overnight. The reaction mixture was concentrated and neutralized with 1M HCl. The
crude was purified by size exclusion column chromatography (100% H2O) and the
desired fractions were collected and lyophilized to give the desired compound.

2,2',2'',2'''-((2,2',2'',2'''((4aR,8R,11aR,15aR,19R,22aR,23R,24R)-icosahydro-8,19-
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[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine-5,11,16,22tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetic acid (3.9). Starting material 3.6
(0.200 g, 0.448 mmol), K2CO3 (0.310 g, 2.24 mmol), ethyl (2-chloroacetyl)glycinate 3.7
(0.402 g, 2.24 mmol), CH3CN (vtot = 7 mL) and MeOH/1M NaOH (vtot =6 mL). The title
compound was obtained as a cream solid (0.221 g, 54%). ESI-TOF m/z calcd for
C42H71N10O12 (M + H)+, calculated 907.5253, found 907.5295.

2,2',2'',2'''-((2,2',2'',2'''((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetic acid (3.19). Starting material
3.17 (0.323 g, 0.954 mmol), K2CO3 (0.659 g, 4.77 mmol), ethyl (2-chloroacetyl)glycinate
3.7 (0.857 g, 4.77 mmol), CH3CN (vtot = 10 mL) and MeOH/1M NaOH (vtot = 9 mL). The
title compound was obtained as a cream solid (0.273 g, 36%). ESI-TOF m/z calcd for
C34H59N10O12 (M + H)+, calculated 799.4314, found 799.4346.

General procedure for metalation. Starting material was suspended in H2O and the
appropriate metal salts added. The pH was adjusted to 7 and the reaction mixture heated
to 50oC and left for overnight. The crude was dialyzed for 3 days and then lyophilized.
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Copper(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((4aR,8R,11aR,15aR,19R,22aR,23R,24R)-icosahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine-5,11,16,22tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.10). Starting material 3.9
(0.034 g, 0.0375 mmol), CuCl2.2H2O (0.0066 g, 0.0413 mmol) and H2O (1 mL). The title
compound was obtained as a blue solid (0.031 g, 86%). ESI-TOF m/z calcd for
C42H68N10O12Cu (M - 2H)+, calculated 967.4314, found 967.4296.

Cobalt(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((4aR,8R,11aR,15aR,19R,22aR,23R,24R)-icosahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine-5,11,16,22tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.11). Starting material 3.9
(0.024 g, 0.0265 mmol), CoCl2.6H2O (0.0069g, 0.029 mmol) and H2O (1 mL). The title
compound was obtained as a purple solid (0.015 g, 58%). ESI-TOF m/z calcd for
C42H68N10O12Co (M - 2H)+, calculated 963.4350, found 963.4392.
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Nickel(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((4aR,8R,11aR,15aR,19R,22aR,23R,24R)-icosahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine-5,11,16,22tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.12). Starting material 3.9
(0.034 g, 0.0375 mmol), NiCl2 (0.0054 g, 0.0413 mmol) and H2O (1 mL). The title
compound was obtained as a green solid (0.026 g, 72%). ESI-TOF m/z calcd for
C42H68N10O12Ni (M - 2H)+, calculated 962.4372, found 962.4348.

Zinc(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((4aR,8R,11aR,15aR,19R,22aR,23R,24R)-icosahydro-8,19[1,2]benzenodibenzo[b,k][1,4,7,10,13,16]hexaazacyclooctadecine-5,11,16,22tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.13). Starting material 3.9
(0.024 g, 0.026 mmol), ZnCl2 (0.0035 g, 0.026 mmol) and H2O (1 mL). The title
compound was obtained as a white solid (0.017 g, 68%). ESI-TOF m/z calcd for
C42H68N10O12Zn (M - 2H)+, calculated 968.4310, found 968.4356.

76

Copper(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.20). Starting material 3.19
(0.030 g, 0.0375 mmol), CuCl2.2H2O (0.0069 g, 0.0413 mmol) and H2O (1 mL). The title
compound was obtained as a blue solid (0.027 g, 84%). ESI-TOF m/z calcd for
C34H56N10O12Cu (M - 2H)+, calculated 859.3375, found 859.3398.

Cobalt(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.21). Starting material 3.19
(0.041 g, 0.051 mmol), CoCl2.6H2O (0.013 g, 0.0547 mmol) and H2O (1 mL). The title
compound was obtained as a purple solid (0.032g, 73%). ESI-TOF m/z calcd for
C34H56N10O12Co (M - 2H)+, calculated 855.3411, found 855.3404.

Nickel(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20-
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tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.22). Starting material 3.19
(0.020 g, 0.025 mmol), NiCl2 (0.0036 g, 0.0275 mmol) and H2O (1 mL). The title
compound was obtained as a green solid (0.014 g, 65%.). ESI-TOF m/z calcd for
C34H56N10O12Ni (M - 2H)+, calculated 854.3433, found 854.3400.

Iron(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.23). Starting material 3.19
(0.020 g, 0.025 mmol), Fe(CF3SO3)2 (0.0088 g, 0.025 mmol) and H2O (1 mL). The title
compound was obtained as a red solid (0.021g, 95%). ESI-TOF m/z calcd for
C34H56N10O12Fe (M - 2H)+, calculated 852.3429, found 852.3394.

Zinc(II)

(2,2',2'',2'''-((2,2',2'',2'''-

((1R,10R,10aR,14aR)-dodecahydro-1,10(ethanoiminoethanoiminoethano)benzo[b][1,4,7,10]tetraazacyclododecine-4,7,17,20tetrayl)tetrakis(acetyl))tetrakis(azanediyl))tetraacetate) (3.24). Starting material 3.19
(0.025 g, 0.031 mmol), ZnCl2 (0.0042 g, 0.031 mmol) and H2O (1 mL). The title
compound was obtained as a white solid (0.018 g, 65%). ESI-TOF m/z calcd for
C34H56N10O12Zn (M - 2H)+, calculated 860.3371, found 860.3356.
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3.4.3 Spectra
S 3.1: 1H NMR Spectrum of 3.4
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S 3.3: COSY Spectrum of 3.4
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S 3.4: HMBC Spectrum of 3.4
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S 3.5: HSQC Spectrum of 3.4
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S 3.6: 1H NMR Spectrum of 3.16

S 3.7: 13C NMR Spectrum of 3.16
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S 3.8: COSY Spectrum of 3.16
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S 3.9: HMBC Spectrum of 3.16

85

S 3.10: HSQC Spectrum of 3.16
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S 3.11: 1H NMR Spectrum of 3.6

S 3.12: 13C NMR Spectrum of 3.6
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S 3.13: 1H NMR Spectrum of 3.17
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S 3.15: 1H NMR Spectrum of 3.9
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S 3.17: r1 relaxivity profile of 3.11
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S 3.18: r2 relaxivity profile of 3.11
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S 3.19: r1 relaxivity profile of 3.12
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S 3.20: r2 relaxivity profile of 3.12
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S 3.21: r1 relaxivity profile of 3.21
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S 3.22: r2 relaxivity profile of 3.21
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S 3.23: r1 relaxivity profile of 3.22
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S 3.24: r2 relaxivity profile of 3.22
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S 3.25: r1 relaxivity profile of 3.23
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S 3.26: r2 relaxivity profile of 3.23
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Chapter 4
4

MRI PARACEST Agents that Improve Amide-based pH
Measurements by Limiting Inner Sphere Water T2
Exchange

4.1 Introduction
The aim of this project was to modulate the pKas of the amide protons and subsequently
the amide CEST effect in DOTAM analogues. This was to be accomplished by
synthesizing DOTAM tetraanilides that had electron-donating groups (EDGs) and
electron-withdrawing groups (EWGs) in the para position of the aniline ring. One may
expect the EWGs of the acetamide arms to make the amide protons more acidic, resulting
in a faster exchange rate with the bulk water protons. On the other hand, EDGs should
slow the rate of exchange of the amide protons with the bulk water protons. On account
of this modulation, it was hoped these agents would be more sensitive to changes within
the biologically relevant pH range, thus resulting in pH responsive PARACEST probes.
It has been previously demonstrated that the bound water exchange rate in PARACEST
agents of Eu3+-tetraamide complexes with one para-substituted aniline arm, can be
modulated electronically using EDGs and EWGs.1 A similar study involving amide
protons has not yet been reported until now.2 As a result of the interest in the CEST effect
due to amide protons, the complexes synthesized here were based on Tm3+ and Dy3+,
which allowed for a larger chemical shift difference from the bulk water, in comparison
to Eu3+.
It was furthermore proposed that these PARACEST agents would not contain a bound
water coordinated to the metal center. This is a highly feasible circumstance owing to the
four aromatic rings of the acetamide pendant arms, which can provide steric bulk to the
complex, thus blocking access of water to the metal center. The lack of a metal bound
water would reduce signal losses due to T2 relaxation. This relaxation is facilitated by T2
exchange of the metal bound water with the surrounding water molecules. The impact of
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this effect may be lessened by using pulse sequences such as the ultra-short echo-time
(UTE) pulse.3 It should be considered that the presence of any other exchangeable
protons such as amide protons would still cause T2 relaxation. However, the extent of
relaxation will be lesser as compared to that of a metal bound water.

4.2 Results and Discussion
4.2.1 Synthesis

Scheme 4.1: Synthetic route to tetraanilide complexes 4.11a,b - 4.15a,b.

The electrophiles 4.1 - 4.5 were synthesized by adding chloroacetyl chloride to the
appropriate aniline in CH3CN while cooling in an ice bath in the presence of K2CO3
(Scheme 4.1). The reactions were stirred overnight at room temperature, then filtered and
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the crude products were recrystallized from methanol.

The average yield of these

reactions was good (ca. 75%).
Syntheses of the tetra-substituted cyclens were performed by mixing cyclen with the
appropriate electrophiles in CH3CN in the presence of K2CO3. It was necessary to heat
the reaction at 55 °C- 80 °C over 1-3 days to ensure complete tetraalkylation. The
progress of these reactions was monitored by UPLC-MS.

When the reaction was

considered complete, the mixtures were cooled and the reaction mixture filtered. It was
realized that the precipitates contained the desired products; therefore, they was washed
with cold water to remove the K2CO3 and other salts. At this point, efforts to recrystallize
these compounds from methanol were unsuccessful due to their highly insoluble nature.
As such, the crude products were used in the next step without further purification.
These tetraalkylated ligands 4.6 - 4.10 were mostly insoluble in a wide range of solvents
such as MeOH, CH3CN and H2O.
The tetra-substituted ligands 4.6 - 4.10 were metalated using salts of Dy3+ and Tm3+ in a
1:1 H2O/dioxane mixture at 80 °C over 4 days. The metalated complexes were subjected
to dialysis against water across a membrane with a 500 Dalton molecular weight cutoff to
remove salts carried through from the previous step as well as any unchelated lanthanide
ion.

The final products were isolated and lyophilized to give white powders, with

exception of the p-NO2 complexes 4.15a,b being yellow powders. Identification of the
metalated products was accomplished by high resolution mass spectrometry along with
their UPLC trace which showed that all of the samples to be homogeneous tetrasubstituted product. After metalation, solubility slightly improved for the Dy3+ and Tm3+
tetraaniline complexes of p-OMe (4.11a,b) and p-H (4.13a,b). Attempts were made to
improve the solubilty of the p-NO2 complexes 4.15a,b for CEST analysis using Tween
20® but these were unsuccessful.
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4.2.2 Crystal Structure
Figure 4.1 shows the X-ray crystal structure of Tm3+-p-OMe complex 4.11a with the
corresponding crystallographic parameters listed in Table 4.1. The crystals were grown
from slow evaporation of a concentrated solution of 4.11a in water. In solution, DOTAlike complexes may adopt two possible coordination isomers. One isomer is the square
antiprismatic (SAP) and the other is the twisted square antiprismatic (TSAP) isomer. The
two isomers can be differentiated by their respective angles between the N-Ln-N and OLn-O planes (α). In the former geometry, that angle is ~ 40o and in the latter, is~ 30o.

(b)

(a)

φ

α

Figure 4.1: Molecular representation of the solid state structure of Tm3+-p-OMe
complex (4.11a) determined by single crystal X-ray studies. Hydrogens have been
omitted for clarity. (a) Top down view of 4.11a. The aniline rings are omitted for
clarity. α indicates the angle created between the planes of N–Ln–N and O–Ln–O
and is listed in Table 4.2 along with selected angles and bond lengths and (b) side on
view of 4.11a showing eightfold coordination of the Tm3+ by the nitrogens of cyclen
and the oxygens of the amide pendant groups. φ denotes the trans O–Ln–O bond
angle.
The solid state structure of the Tm3+-p-OMe complex 4.11a revealed that α was 27o, thus
indicating a TSAP geometry (Figure 4.1). The structure also revealed that there was no
bound water coordinated to Tm3+, therefore that geometry is more correctly denoted as
TSAP'. Lanthanide complexes based on the DOTA core structure, typically have eight
coordination sites due to the four nitrogens of the macrocycle and the four oxygens from
the pendant arms. These atoms coordinate to the metal center and the ninth coordination
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site on the metal is typically occupied by a solvent molecule such as water. The distance
between the centeroids of the O4 and N4 planes has a distance of 2.47 Å, which is
comparable to other TSAP structures. This distance in SAP structures is ~2.35 Å.4, 5 The
distance between the centeroid of the four nitrogen atoms of the macrocycle and Tm3+ is
1.38 Å, which is shorter then a series of previously reported SAP DOTAM complexs
(Dy3+ = 1.59 Å, Nd3+ = 1.66 Å, Tb3+ = 1.59 Å, Yb3+ =1.56 Å).6
Table 4.1: Crystal data and structure refinements for 4.11a.
Formula
Formula Weight (g/mol)
Crystal Dimensions (mm )
Crystal Colour and Habit
Crystal System
Space Group
Temperature, K

C44H67Cl3N8O13Tm
1191.34
0.27 × 0.18 × 0.08
colourless prism
triclinic
P -1
110

a, Å
b, Å
c, Å
α,°
β,°
γ,°
V, Å3
Number of reflections to determine final unit cell
Min and Max 2q for cell determination,
°Z
F(000)
ρ (g/cm)

10.948(3)
14.438(3)
17.436(5)
77.345(10)
78.428(9)
85.152(10)
2632.1(12)
9059
4.88, 64.1
2
1222
1.503

λ, Å, (MoKa)
μ, (cm-1)

0.71073
1.904

Additionally, it was noted that the angles at the metal center (φ, O1–Tm–O3 and O2–Tm–
O4) was about 123o (Table 4.2). This angle is expected to be at least 135o.4, 7 The lower φ
may be as a result of Tm3+ being positioned lower in the chelate cavity and the four
oxygens of the carbonyl pendant arms being wrapped around the metal. This in turn
blocked access to the metal by the water molecule. Taking into account that the chemical
shift due of the amide CEST signal is distance dependent, the compact nature of the
complex may have led to a highly shifted signal.8
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Table 4.2: Summary of torsion angle α (°) and selected bond lengths (Å) for Tm3+-pOMe (4.11a).
Average α angle
N1-C-C-O1
N2-C-C-O2
N3-C-C-O3
N4-C-C-O4
N1-Tm
N2-Tm
N3-Tm
N4-Tm
O1-Tm
O2-Tm
O3-Tm
O4-Tm
φ angle O1–Tm–O3
φ angle O2–Tm–O4
Centeroid O4–Tm
Centeroid N4–Tm
Centeroid O4–centeroid
N4

26.95
12.4(3)
15.1(4)
14.7(4)
2.9(3)
2.508(2)
2.492(2)
2.469(3)
2.500(3)
2.295(2)
2.245(2)
2.313(2)
2.265(2)
123.64(7)
122.43(8)
1.087
1.382
2.470

4.2.3 Magnetic Studies
CEST evaluation
As a consequence of insolubility, only the Tm3+ and Dy3+ tetraaniline complexes of pOMe (4.11a,b) and p-H (4.13a,b) were further evaluated. CEST data for these complexes
were acquired within the pH range of 6.5 to 9.0 for 4.13a,b and the pH range of 5.1 to 8.0
for 4.11a,b (Figure 4.2). These ranges were chosen because of the observation that the
maximum CEST effect was close to pH 8.0 for the former and the latter had the
maximum CEST effect between 7.0 and 7.5.
A 12% CEST signal was observed for the Tm3+-p-H complex 4.13a, while two signals of
17% and 12% were observed for Tm3+-p-OMe complex 4.11a. These signals may be
attributed to the presence of the two conformational isomers in solution, that is, the SAP'
and TSAP' isomers, respectively. This particular assignment was based on the previous
observations for a series of DOTAM alkyl amides.9, 10
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Figure 4.2: CEST spectra of (a) Tm3+-p-OMe complex 4.11a over the pH range of
5.1–7.0 and (b) Tm3+-p-H complex 4.13a over the pH range of 6.5–9.0. CEST spectra
were acquired at 37 oC, with a 15 uT, 5 s presaturation pulse, 20 mM.

The CEST results for the Dy3+ tetraaniline complexes of p-OMe (4.11b) and p-H (4.13b)
were more customary. While the Dy3+-p-H complex 4.13b still had one signal of 6%, the
Tm3+-p-OMe complex 4.11b now had one signal of 3%. A summary of the CEST result
for the Tm3+ and Dy3+ tetraaniline complexes of p-OMe (4.11a,b) and p-H (4.13a,b) are
shown in Table 4.3.
Table 4.3: CEST % measured at pH 7, 37 °C, 20 mM with a 15 µT, 5 s continuous
wave saturation pulse.
Agent
4.11a
4.13a
4.11b
4.13b

ppm (δ)
-43
-83
-41
74
70

CEST %
17%
12%
12%
3%
6%
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(a)

(b)

Figure 4.3: Maximum CEST effect as a function of pH (a) Tm3+-p-OMe complex
4.11a shows a pH maximum at 7.5 for the signal at -43 ppm and at 7.0 for the signal
at -83 ppm and (b) Tm3+-p-H complex 4.13a shows a pH maximum at 8.0.

Figure 4.3 shows the changes in the CEST effect of agents Tm3+-p-OMe complex 4.11a
and Tm3+-p-H complex 4.13a as a function of the pH ranges measured. The signal for the
4.11a SAP' amide (-43 ppm) has a maximum signal at pH 7.5 compared to the TSAP'
amide (-83 ppm) with its maximum signal at a slightly more acidic pH of 7.0. A similar
effect has been previously reported for DOTAM agents, in which the signal having the
greater chemical shift displayed a maximum CEST signal at lower pH, in comparison to
the signal with a smaller chemical shift.11
The presence of the two signals seen for the Tm3+-p-OMe complex 4.11a was
encouraging for ratiometric analysis. A ratiometric approach would eliminate the CEST
effect dependency on concentration, thus allowing the agent to be used as a biological
reporter.12, 13 Unfortunately, preliminary results from the ratiometric studies indicated that
this cannot be avoided. The CEST response for this complex between pH 6 and 7 seemed
to be concentration dependent, which is highly likely due to the solubility issues. At high
concentrations, 4.11a is very insoluble but at lower concentrations, the solubility
improves. These discrepancies preclude the use of this agent for ratiometric purposes.
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Relaxometric studies
Table 4.4: r1 and r2 values of the Tm3+ based agents at 37 °C, pH 7.
Agent
Tm3+-p-OMe (4.11a)
Tm3+-p-H (4.13a)

r1 (s-1 mM-1)
0.05
0.06

r2 (s-1 mM-1)
0.36
0.67

The lack of a bound water in the Tm3+-p-OMe complex 4.11a should be advantageous in
amide- based PARACEST imaging as water exchange contributing to the T2 shortening
mechanism has been eliminated. As mentioned earlier, the exchange of amide protons of
the acetamide pendant arm still contributes to the T2 relaxation of bulk water. However,
the extent to which this happens is less compared to the highly shifted bound water (δ =
500 ppm).14 The associated r1 and r2 values for Tm3+-p-OMe (4.11a) and Tm3+-p-H
(4.13a) are provided in Table 4.4. The low values shown are representative of the lack of
an inner sphere water molecule in these complexes. Moreover, Tm3+ is not known to act
as a T1 relaxation enhancer; therefore, it is not surprising that they did not produce a
strong T1 relaxation of the bulk water.15

4.3 Conclusions
A series of Dy3+ and Tm3+ para-substituted tetraaniline contrast agents were synthesized
for the testing of their ability to respond to pH changes in the physiological pH range.
Poor solubility of many of the compounds limited the possible measurements and
prevented the complete analysis of structure and effects. As such, a proper analysis of the
electronic effects on the pKas of the amide protons could not be performed. Four of the
compounds were soluble enough for further investigation. It was observed that the
unsubstituted anilines (Dy3+ and Tm3+-p-H) had a maximum CEST effect at a pH near 8,
while the maximum CEST effect for both the Dy3+ and Tm3+-p-OMe agents was between
pH 7 - 7.5. A crystal structure indicated that the geometry of Tm3+-p-OMe complex is
TSAP', which potentially leads to the highly shifted signal at -83 ppm. A signal for a
Tm3+ agent above 100 ppm has been previously observed,10 but due to the inability to
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grow a crystal suitable for analysis by X-ray crystallography, the presence of an inner
sphere water cannot be determined. A concentration and pH study was attempted to
determine if the Tm3+-p-OMe complex could be used as a ratiometric agent to measure
pH in vivo, independent of concentration, but due to solubility limitations, no suitable
measurements could be performed. With the lack of inner sphere water, the Tm3+ aniline
agents may produce appreciable amide CEST contrast without decreasing image signal
intensity due to lowering of the bulk water T2 relaxation time constant.

4.4 Supplemental Information
4.4.1 General Experimental
General synthetic details can be found in Appendix 1.
CEST and Relaxivity Experiments
All samples were studied at 20 mM concentration, 37 °C.CEST spectra (Tm3+ and Dy3+)
were acquired using a 15µT, 5s continuous wave presaturation pulse at offset frequencies
ranging from -100 to 100 ppm in steps of 1 ppm. T1 relaxation time constant
measurements were made for 4 different concentrations (1, 2, 4, 8 mM) of CA using an
inversion recovery sequence (10 inversion times in the range of 10 ms – 10 s) with a 20
second repetition time to ensure full recovery, pH 7 and 37 °C. T2 relaxation time
constant measurements were made for 4 different concentrations (1, 2, 4, 8 mM) of CA
using a CPMG pulse sequence (10 train echo times in the range of 10 ms – 10 s) with a
20 second repetition time to ensure full recovery, pH 7 and 37 °C.

4.4.2 Synthetic Procedures
General procedure for synthesis of N-aryl-chloroacetamides. Anilines 4.1 - 4.5 (7.84
mmol) and K2CO3 (15.68 mmol) were suspended in CH3CN (50 mL) and cooled to 0oC
in an ice bath while stirring. Chloroacetyl chloride (15.68 mmol) was added dropwise and
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reaction mixture warmed to room temperature and left stirring overnight. Reaction
mixture was filtered and the filtrate collected and concentrated. The residue was
recrytallized from hot CH3OH.

2-Chloro-N-(4-methoxyphenyl)acetamide (4.1). The title compound was
obtained as silver crystals (1.29 g, 82%) 1H NMR (400 MHz, DMSO-d6): δ 10.17 (1H, s);
7.51 (2H, d, J = 8.6 Hz); 6.90 (2H, d, J = 8.6 Hz); 4.22 (2H, s); 3.72 (3H, s). 13C NMR
(100 MHz, DMSO-d6): δ 164.5, 156.0, 132.0, 121.4, 114.3, 55.6. 43.9. ESI-TOF m/z
calcd for C9H11ClNO2 (M+H)+, calculated 200.0478, found 200.0477.

2-Chloro-N-(p-tolyl)acetamide (4.2). The title compound was obtained as
white crystals (1.08 g, 75%) 1H NMR (400 MHz, DMSO-d6): δ 10.21 (1H, s); 7.50 (2H,
d, J = 7.4 Hz); 7.13 (2H, d, J = 7.4 Hz); 4.24 (2H, s); 2.26 (3H, s). 13C NMR (100 MHz,
DMSO-d6): δ 164.8, 136.4, 133.2, 129.6, 119.8, 44.0, 20.8. ESI-TOF m/z calcd for
C9H11ClNO (M+H)+, calculated 184.0529, found 184.0524.

O
HN

Cl

2-Chloro-N-phenylacetamide (4.3). The title compound was obtained as white
crystals (1.06 g, 80%) 1H NMR (400 MHz, DMSO-d6): δ 10.36 (1H, s); 7.60 (2H, d, J =
7.4 Hz); 7.33 (2H, t, J =7.4 Hz); 7.08 (1H, t, J = 7.4 Hz); 4.26 (2H, s,). 13C NMR (100
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MHz, DMSO-d6): δ 165.0, 138.9, 129.2, 124.2, 119.8, 44.0. ESI-TOF m/z calcd for
C8H9ClNO (M+H)+, calculated 170.0373, found 170.0366.

2-Chloro-N-(4-chlorophenyl)acetamide (4.4). The title compound was
obtained as white crystals (1.08 g, 68%) 1H NMR (400 MHz, DMSO-d6): δ 10.43 (1H, s);
7.62 (2H, d, J = 8.6 Hz); 7.38 (2H, d, J = 8.6 Hz); 4.26 (2H, s).

13

C NMR (100 MHz,

DMSO-d6): δ 165.2, 137.8, 129.2, 127.9, 121.3, 43.9. ESI-TOF m/z calcd for C8H8Cl2NO
(M+H)+, calculated 203.9983, found 203.9983.

2-Chloro-N-(4-nitrophenyl)acetamide (4.5). The title compound was
obtained as yellow crystals (1.80 g, 79%) 1H NMR (400 MHz, DMSO-d6): δ 10.97 (1H,
s); 8.22 (2H, d, J = 9.0 Hz); 7.84 (2H, d, J = 9.0 Hz); 4.35 (2H, s). 13C NMR (100 MHz,
DMSO-d6): δ 166.0, 145.0, 143.0, 125.4, 119.5, 44.0. ESI-TOF m/z calcd for
C8H8ClN2O3 (M+H)+, calculated 215.0223, found 215.0220.

General

procedure

for

synthesis

of

tetrakis-N-aryl-acetamides.

1,4,7,10-

tetraazacyclododecane (cyclen), (0.5 mmol) and K2CO3 (2.25 mmol) were suspended in
CH3CN (12 mL) and acetamides 4.1 - 4.5 (2.25 mmol) dissolved in CH3CN (3 mL) were
added. The reaction mixture was heated to 55oC-80oC and left for 1-3 days. Reaction
mixture was filtered and the precipitate washed with H2O then collected and dried.
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2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxyphenyl)acetamide)
(4.6). The title compound was obtained as a white powder (0.389 g, 94%) 1H NMR (400
MHz, DMSO-d6): 10.04 (4H, broad s); 7.51 (8H, s); 6.80 (8H, s); 3.68 (16H, s,); 3.25
(12H, s); 2.84 (8H, broad s).

13

C NMR (100 MHz, DMSO-d6): δ 168.8, 155.1, 131.7,

120.8, 113.6, 58.1, 55.0, 52.0. ESI-TOF m/z calcd for C44H57N8O8 (M+H)+, calculated
825.4299, found 825.4284.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane1,4,7,10-tetrayl)tetrakis(N-(p-tolyl)acetamide) (4.7). The title compound was obtained
as a white powder (0.375 g, quantitative) 1H NMR (400 MHz, DMSO-d6): δ 10.05 (4H,
broad s); 7.47 (8H, d, J = 6.6 Hz); 7.03 (8H, d, J = 6.6 Hz); 3.26 (16H, s); 2.82 (8H,
broad s); 2.22 (12H, s).

13

C NMR (100 MHz, DMSO-d6): δ 169.0, 135.9, 131.9, 128.7,

119.3, 58.1, 52.3, 20.1. ESI-TOF m/z calcd for C44H57N8O4 (M+H)+, calculated 761.4503,
found 761.4529.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10tetrayl)tetrakis(N-phenylacetamide) (4.8). The title compound was obtained as a white
powder (0.348 g, quantitative) 1H NMR (400 MHz, DMSO-d6): δ 10.32 (4H, broad s);
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7.61 (8H, d, J = 7.8 Hz); 7.22 (8H, t, J =7.8 Hz); 7.01 (4H, t, J = 7.8 Hz); 3.38 (16H, s);
2.81 (8H, broad s). 13C NMR (100 MHz, DMSO-d6): δ 169.3, 138.5, 128.3, 123.0, 119.3,
58.1, 51.9. ESI-TOF m/z calcd for C40H49N8O4 (M+H)+, calculated 705.3877, found
705.399.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane1,4,7,10-tetrayl)tetrakis(N-(4-chlorophenyl)acetamide) (4.9). The title compound was
obtained as a white powder (0.394 g, 94%)1H NMR (400 MHz, DMSO-d6): δ δ 10.6 (4H,
broad s); 7.64 (8H, d, J = 8.8 Hz); 7.26 (8H, d, J = 8.8 Hz); 3.37 (16H, s); 2.78 (8H,
broad s).
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C NMR (100 MHz, DMSO-d6): δ 169.5, 137.4, 128.1, 126.6, 120.8, 57.8,

51.7. ESI-TOF m/z calcd for C40H45Cl4N8O4 (M+H)+, calculated 841.2318, found
841.2325.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane1,4,7,10-tetrayl)tetrakis(N-(4-nitrophenyl)acetamide) (4.10). The title compound was
obtained as a yellow powder (0.437 g, quantitative) 1H NMR (400 MHz, DMSO-d6): δ
10.69 (4H, broad s); 8.10 (8H, s); 7.81 (8H, s); 3.39 (16H, s); 2.87 (8H, broad s).

13

C

NMR (100 MHz, DMSO-d6): δ 170.2, 144.5, 142.0 124.3, 118.7, 57.7, 52.0. ESI-TOF
m/z calcd for C40H45N12O12 (M+H)+, calculated 885.3280, found 885.3254.
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General procedure for synthesis of metalated compounds. Compounds 4.6 - 4.10
(0.07 mmol) were dissolved (or suspended) in dioxane/H2O (1:1) (4 mL total) then the
appropriate lanthanide chloride salts (0.07 mmol) added. The pH was adjusted to 6 and
the reaction mixture heated to 60-80oC and left for 1 - 4 days. The crude was dialysed for
3 days then lyophilized to obtain desired products.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxyphenyl)acetamide),
thulium(III) salt (4.11a). The title compound was obtained as a white powder (58 mg,
83%). ESI-TOF m/z calcd for C44H54N8O8Tm (M-2H)+, calculated 991.3407, found
991.3387.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(p-tolyl)acetamide),

thulium(III)

salt (4.12a). The title compound was obtained as a white powder (30 mg, 46%). ESI-TOF
m/z calcd for C44H54N8O4Tm (M-2H)+, calculated 927.3610, found 927.3647.
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2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane1,4,7,10-tetrayl)tetrakis(N-phenylacetamide), thulium(III) salt (4.13a). The title
compound was obtained as a white powder (41 mg, 67%). ESI-TOF m/z calcd for
C40H46N8O4Tm (M-2H)+, calculated 871.2984, found 871.2974.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-chlorophenyl)acetamide),
thulium(III) salt (4.14a). The title compound was obtained as a white powder (40 mg,
56%). ESI-TOF m/z calcd for C40H42Cl4N8O4Tm (M-2H)+, calculated 1007.1425, found
1007.1412.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-nitrophenyl)acetamide),
thulium(III) salt (4.15a). The title compound was obtained as a yellow powder (61mg,
82%). ESI-TOF m/z calcd for C40H42N12O12Tm (M-2H)+, calculated 1051.2387, found
1051.2408.
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2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxyphenyl)acetamide),
dysprosium(III) salt (4.11b). The title compound was obtained as a white powder (53
mg, 77%). ESI-TOF m/z calcd for C44H54N8O8Dy (M-2H)+, calculated 986.3356, found
986.3383.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(p-tolyl)acetamide),
dysprosium(III) salt (4.12b). The title compound was obtained as a white powder (43
mg, 69%). ESI-TOF m/z calcd for C44H54N8O4Dy (M-2H)+, calculated 922.3560, found
922.3586.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane1,4,7,10-tetrayl)tetrakis(N-phenylacetamide), dysprosium(III) salt (4.13b). The title
compound was obtained as a white powder (45 mg, 75%). ESI-TOF m/z calcd for
C40H46N8O4Dy (M-2H)+, calculated 866.934, found 866.2903.
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2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-chlorophenyl)acetamide),
dysprosium(III) salt (4.14b). The title compound was obtained as a white powder (49
mg, 70%). ESI-TOF m/z calcd for C40H42Cl4N8O4Dy (M-2H)+, calculated 1002.1375,
found 1002.1343.

2,2',2'',2'''-(1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-nitrophenyl)acetamide),
dysprosium(III) salt (4.15b). The title compound was obtained as a yellow powder (45
mg, 62%). ESI-TOF m/z calcd for C40H42N12O12Dy (M-2H)+, calculated 1046.2337,
found 1046.2336.
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4.4.3 Spectra
S 4.1: 1H-NMR Spectrum of 4.1
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S 4.3: 1H-NMR Spectrum of 4.2
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S 4.5: 1H-NMR Spectrum of 4.3
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S 4.7: 1H-NMR Spectrum of 4.4
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S 4.9: 1H-NMR Spectrum of 4.5
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S 4.11: 1H-NMR Spectrum of 4.6
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S 4.13: 1H-NMR Spectrum of 4.7
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S 4.15: 1H-NMR Spectrum of 4.8
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S 4.17: 1H-NMR Spectrum of 4.9
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S 4.19: 1H-NMR Spectrum of 4.10
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S 4.20: 13C-NMR Spectrum of 4.10
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Chapter 5
5

Dysprosium(III) and Thulium(III) Complexes of DO3Amonoanilides: An Investigation of Electronic Effects on
their Relaxometric and Amide-based PARACEST
Properties

5.1 Introduction
As described in Chapter 4, a study of DOTAM-tetraanilide PARACEST agents which
were varied about their para (p-)-substituents was completed.1 The aim of that work was
to modulate the amide proton exchange rate to increase the CEST contrast produced by
these protons. Unfortunately, with the exception of the Dy3+- and Tm3+-p-H and -p-OMe
complexes (Figure 5.1), the other complexes were insoluble and could not be further
studied.1

Figure 5.1: Chemical structures of some complexes discussed in this work.

In order to produce water soluble complexes, a series of analogues, the DO3Amonoanilide ligands, was prepared. The intent was to utilize this series to investigate the
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influence of the nature of the para-substituent on the amide proton CEST signal. These
complexes represent a simplified system compared to the tetraanilide complexes
possessing not only aqueous solubility but also only a single carboxamide proton. The
presence of three acetate arms and the use of Tm3+ and Dy3+ would produce large LIS
and engender fast water exchange at the metal center. However, the effect on exchange
of the amide proton should be smaller and hence a CEST signal is expected. Congruent
with this expectation, is the observation of an amide proton based CEST signal for the
Yb3+-DO3A-oAA complex (Chart 1).2, 3
The lone acetamide arm was designed with the para-substituted anilines spanning a large
range of electronic effects ranging from strong electron-donating groups (EDG, e.g. NMe2) to powerful electron-withdrawing groups (EWGs, e.g. -NO2). Anilines that are
substituted in the para position on the aromatic ring can provide information about
electronic effects, charge state (pKa) and polarity. Since the CEST effect is due to the
single carboxamide proton, these studies should provide insight regarding the amide pKa
and provide some insight on the ability to tune the pKa and CEST effect to biologically
relevant pHs potentially laying the foundation for development of a pH responsive
PARACEST contrast agent.
In lanthanide complexes, where CEST due to amide protons is to be observed, one may
expect EWGs of the acetamide arm to make the amide proton more acidic. This should
result in a faster exchange with bulk water. On the other hand, the opposite effect should
be observed for EDGs: the amide proton becomes more basic resulting in slower
exchange with the surrounding water. According to Terreno et al., an increase in pH up to
9 increases the amide exchange rate and subsequently, the amide CEST.4 It is expected
that EWGs would allow for a decrease in the pH at which the maximum CEST effect
occurs. This feature would make agents possessing these functional moieties more
applicable as pH sensors for detecting biological anomalies, such as cancerous tissues,
which have an acidic extracellular pH.5
Our second focus was to examine the influence of the nature of the para-substituent on
the complex relaxivity. These complexes were expected to have fast water exchange at
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the metal center that may be affected by the electronics of the single amide arm. For
example, EDGs are envisioned to promote faster exchange of bound water due to an
increase in electron density at the metal center, while the converse would ensue with the
presence of EWGs. These effects should be apparent in the relaxivity measurements. In
support of this notion, Ratnakar et al. have reported that Eu3+-tetraamide complexes with
one para-substituted aniline arm, can electronically affect the CEST effect due to a bound
water molecule.6

5.2 Results and Discussion
5.2.1 Synthesis
Treatment of Et3DO3A with the chlorine-containing electrophiles 5.1 - 5.5,1 in the
presence of K2CO3, gave the desired bifunctional compounds 5.6 - 5.10 in low to
moderate yields after purification by column chromatography (Scheme 5.1). All the esterprotected compounds 5.6 - 5.9 were subjected to saponification at 60oC without any
problems, with the exception of 5.10. The saponified compounds 5.11 - 5.14 were
obtained with excellent yields (Scheme 5.1). In contrast, the amide bond of 5.10
hydrolysed, leading to the formation of DOTA (Figure 5.1), as seen by UPLC.
Consequently, the ethyl groups of compound 5.10 were removed under milder conditions
at 5oC7 and compound 5.19 was obtained with excellent yield (Scheme 5.2).
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Scheme 5.1: Conditions for synthesis of contrast agents 5.15a,b - 5.18a,b.

Scheme 5.2: Conditions for synthesis of contrast agents 5.20a,b and 5.21a,b.
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Metalation of the ligands 5.11 - 5.14 with lanthanide salts of Tm3+ and Dy3+, afforded the
Tm3+ complexes 5.15a - 5.18a and Dy3+ 5.15b - 5.18b in moderate to good yields
(Scheme 5.1). In order to prevent the hydrolysis of the amide bond, as seen previously
during the saponification of 5.10, the metalation of ligand 5.19 with Tm3+ and Dy3+ was
performed at room temperature and 5.20a,b were obtained in good yield (Scheme 5.2).
The metalated complexes 5.20a,b were subjected to catalytic hydrogenation to produce
5.21a,b in excellent yields (Scheme 5.2).

5.2.2 CEST Measurements of Tm3+ Complexes
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Figure 5.2: (a) CEST spectra of 5.15a - 5.18a and 5.20a - 5.21a at pH 7.00 ± 0.03 and
(b) CEST spectra of 5.15a - 5.18a and 5.20a - 5.21a at pH 8.00 ± 0.03. CEST spectra
were acquired at 37oC, with a 15 μT, 2 s saturation pulse, 10 mM in D2O/H2O (9:1).
Data was processed with Origin® software by performing a Lorentzian fitting of the
raw data.

The CEST data for the Tm3+ compounds were obtained at pH 6, 7, 8 and 9. CEST signals
were not observed at pH 6 and 9 (data not shown), however, there were signals at pH 7
and 8 (Figure 5.2). The magnitude of the CEST effect ranged from 1 - 8% at these pH
values, with the p-H complex 5.17a having the highest signal of almost 8% at pH 8.
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While these values may be considered low, only a 3-5% change in the water signal
intensity is needed to see contrast in an MR image. 5
CEST signal intensity as a function of EDG/EWG
Figure 5.3 shows the trend in CEST signal intensity with respect to the Hammett
substituent constants associated with groups in the para position (δpara). Hammett
substituent constants give a measure of the total electronic (polar) effect exerted by a
substituent on the aromatic ring, in comparison to the absence of the substituent.

8, 9

These values are derived from the rate of equilibrium of the ionization of unsubstituted
benzoic acid and that of a substituted benzoic acid.8, 9 A δpara value of zero (p-H) indicates
no electronic effect, while increasing negative δpara values indicate EDGs (increasing
order of strength: p-OMe, p-NH2 and p-NMe2). On the other hand, increasing positive
δpara values indicate EWGs (increasing order of strength: p-Cl and p-NO2).
8
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Figure 5.3: CEST intensity with respect to σpara at 37oC and pH 7.00 ± 0.03 and 8.00
± 0.03 for 5.15a - 5.18a and 5.20a - 5.21a. CEST spectra were acquired at 37oC, with
a 15 μT, 2 s saturation pulse, 10 mM in D2O/H2O (9:1).

At pH 7, with the exception of the p-NH2 complex 5.21a, which displayed no CEST
signal, the presence of EDGs led to an increase in the amide CEST effect, in comparison
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to the p-H complex 5.17a. At pH 8, the CEST effect was greatest for the complexes
5.15a, 5.16a and 5.21a. However, their CEST effect was lower than that of the p-H
complex 5.17a. These results seem to support the hypothesis made earlier. The increased
electron-density, due to EDGs, resulted in the amide proton being less acidic, therefore
requiring a higher pH for deprotonation and subsequent exchange.
At pH 7, CEST signals were seen for both 5.18a and 5.20a, which bore EWGs. Both
complexes gave higher signals in contrast to the p-H complex 5.17a. At pH 8, there was a
reduction in the signal of the p-Cl complex 5.18a and a complete disappearance of the
signal for the p-NO2 complex 5.20a, (as compared to the p-H complex 5.17a). These
observations also appear to be in agreement with the afore-mentioned expectations that
EWGs should lead to more acidic amide protons due to lower pKas. At pH 8, the acidic
proton seems to be exchanging rather quickly with the bulk water, thereby negatively
affecting the CEST signal and causing obliteration of the signal. The reduction rather
than eradication of the CEST signal of the p-Cl complex 5.18a implies that the amide
proton exchange rate is still within the limits of the rate requirement for a CEST signal to
be generated. Thus, these EWGs allowed a maximum CEST effect to be seen at pH 7
instead of at pH 8 or 9.
The pKas (unknown) for all these complexes are prone to be dissimilar, even although
there are some similarities in pH where the maximum CEST signal occurs. From these
results, one may infer that there are also similarities in the amide proton exchange rates.
The interesting phenomena of the p-NO2 complex 5.20a having a CEST signal at pH 7
and no signal at pH 8 (vice versa for the p-NH2 complex 5.21a), may serve as a starting
point for the design of a potential dual pH and redox probe using more than one p-NO2
substituents. The reduced CEST effect in the p-NH2 complex 5.21a as compared to pNO2 5.20a, has been similarly demonstrated for the Eu3+-DOTAM-p-NO2 and -p-NH2
monoaniline complexes (Figure 5.1) reported by Ratnakar et al.6
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Observed chemical shift as a function of EDG/EWG
The chemical shift at which the amide CEST signal arises in Tm3+-DOTAM complexes is
-51 ppm.4 The chemical shifts observed for the CEST signals of the Tm3+- DO3Amonoaniline complexes 5.15a - 5.18a and 5.20a - 5.21a fall close to this expected value.
Furthermore, it was observed that the chemical shifts of these complexes were
independent of pH (Table 5.1). In comparison to the p-H complex 5.17a at -53 ppm (at
pH 7 and 8), the EDGs had upfield chemical shifts and the EWGs had downfield
chemical shifts. Surprisingly at pH 7, the p-NO2 complex 5.20a had the most downfield
chemical shift at -46 ppm. The slight downfield shift produced by the EWGs and upfield
shift produced by the EDGs are likely a result of shielding effects propagated through the
aromatic ring system to the amide proton rather than changes in the chelate conformation
which would result in larger chemical shift changes, vide infra.
Table 5.1: Chemical shifts (δ) of Tm3+ based agents 5.15a - 5.18a and 5.20a - 5.21a at 37°C
and pH 7.00 ± 0.03 and 8.00 ± 0.03.
δ (ppm)
7.00 ± 0.03
8.00 ± 0.03
p-NMe2
-55
-55
p-NH2
n.o.
-56
p-OMe
-54
-54
p-H
-53
-53
p-Cl
-52
-51
p-NO2
-46
n.o
n.o. indicates not observed

The Yb3+-DO3A-oAA complex (Figure 5.1) reported had two signals, each due to the
amide proton and the o-NH2 substituent (δ (ppm) = -11 and +8 ppm, respectively; pH 7,
37oC).2 A single signal for the p-NH2 complex 5.21a was only observed at pH 8 (37oC).
The difference in the number of signals seen in both complexes may be attributed to the
position of the NH2 group, rather than pH. In order for a signal to be generated by the
NH2 group, intramolecular hydrogen-bonding with the carboxylate arm may be
necessary.10 In complex 5.21a, the NH2 group in the para position is not conducive to
intramolecular hydrogen-bonding with a carboxylate arm, therefore, no CEST signal was
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seen for these exchangeable protons. In contrast, the Yb3+-DO3A-oAA complex has the
NH2 group in the ortho position, an ideal location for this interaction and thus, an
additional CEST signal for these protons was observed. The small chemical shift
difference in Yb3+-DO3A-oAA complex is a shortcoming of using Yb3+, since the signals
were close to that of the bulk water signal.
As previously reported, Tm3+-tetraaniline-p-H complex had a CEST signal at -41 ppm.
The Tm3+-tetraaniline-p-OMe complex had two CEST signals at -43 and -83 ppm due to
the square antiprismatic (SAP) and twisted square antiprismatic (TSAP) isomers,
respectively.1 The solid state structure of the Tm3+-tetraaniline p-OMe complex indicated
no bound water, therefore those geometries are more correctly denoted as SAP' and
TSAP'.1 Only one signal was seen in the Tm3+- DO3A complexes 5.15a - 5.18a and
5.20a - 5.21a. Hence, this suggests that there is only one isomer (most likely SAP)
present in solution.
CEST signal were not produced by the Dy3+ complexes as the T2 relaxation was too
great, thus no comparisons to the Tm3+ complexes can be made.

5.2.3 Relaxometric Evaluation of Dy3+ and Tm3+ Complexes
Tm3+ Complexes
The relaxivity data for the Tm3+ complexes 5.15a - 5.18a and 5.20a - 5.21a was acquired
and these results are seen in Table 2. These low relaxivity values are comparable to those
reported for the complexes of Tm3+- tetraaniline-p-H (r1 = 0.06 mM-1s-1 and r2 = 0.66
mM-1s-1) and -p-OMe (r1 = 0.05 mM-1s-1 and r2 = 0.40 mM-1s-1).1 In comparison to the pH complex 5.17a, the r1 values indicated an overall slight increase for EDGs and a slight
decrease for EWGs (Figure 5.4). On the other hand, with respect to 5.17a, both EWGs
and EDGs showed a decrease in r2, with the exception being the p-NMe2 complex 5.15a
(Figure 5.4).
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Table 5.2: r1 and r2 values of Tm3+ based agents 5.15a - 5.18a and 5.20a - 5.21a at
25°C and pH 7.00 ± 0.03
p-NMe2
p-NH2
p-OMe
p-H
p-Cl
p-NO2

-1 -1

(mM-1 s-1)
0.19
0.09
0.12
0.15
0.15
0.12

0.24

r1

0.22

r2

0.20

relaxivity (mM s )

r1 (mM-1 s-1) r2
0.06
0.06
0.10
0.05
0.03
0.03

p-NMe2

0.18
p-H

0.16
0.14

p-Cl
p-NO2

p-OMe

0.12
0.10

p-NH2

0.08
0.06
0.04
0.02
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Figure 5.4: r1 and r2 with respect to σpara at 25°C and pH 7.00 ± 0.03 for 5.15a 5.18a and 5.20a - 5.21a.

The relationship between r2 and the strengths of the EDGs or EWGs, is not
straightforward. A maximal value for p-H complex 5.17a (or p-Cl complex 5.18a) is
observed with falling off as │σpara │> 0 with the exception for p-NH2 complex 5.20a
Dy3+ complexes
Dy3+ complexes have been shown to act as T2 shortening agents.11 This is evident as
these agents 5.15b - 5.18b and 5.20b - 5.21b had much higher r2 than r1 values (Table
5.3). In particular, the p-OMe 5.16b and p-H 5.17b complexes had r2 values of
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approximately twice that of the other complexes. These r2 values were also higher in
comparison to Dy3+-DOTA (r2 = 1.5 mM-1 s-1 at 22oC; Figure 5.1),11 indicating that
having at least one amide arm is advantageous. This assumption was made based on
previous results by Soesbe et al., where derivatives of Dy3+-DOTA-glyn (Figure 5.1),
with n = 2, 3 and 4 had r2 values of 18.8 mM-1 s-1, 4.2 mM-1 s-1 and 1.4 mM-1 s-1,
respectively, at 22oC.11
Table 5.3: r1 and r2 values of Dy3+ based agents 5.15b - 5.18b and 5.20b - 5.21b at 25
°C and pH 7.00 ± 0.03.
p-NMe2
p-NH2
p-OMe
p-H
p-Cl
p-NO2

r1 (mM-1 s-1) r2 (mM-1 s-1)
0.2
2.6
0.1
2.0
0.2
4.5
0.3
7.0
0.1
3.4
0.1
2.3

p-H

7.5

0.30

(a)

6.5

(b)

5.5

p-OMe

0.20

-1 -1

p-NMe2

0.15

p-Cl
p-NO2

0.10

p-H

6.0

r2 (mM s )

-1 -1

r1 (mM s )

0.25

7.0

5.0
4.0

2.5
2.0

0.05
-1.0 -0.8 -0.6 -0.4 -0.2 0.0

0.2

0.4

0.6

0.8

1.0

p-Cl

3.5
3.0
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Figure 5.5: (a) r1 with respect to σpara at pH 7.00 ± 0.03 for 5.15b - 5.18b and 5.20b 5.21b and (b) r2 with respect to σpara at pH 7.00 ± 0.03 for 5.15b - 5.18b and 5.20b 5.21b.
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The r1 values with respect to δpara of both the EDGs and EWGs substituents showed a
decrease in comparison to the unsubstituted p-H complex 5.17b. This trend was similarly
observed for the r2 values. Nevertheless, there was an inverse relationship between the
strengths of the groups and the r1 and r2 values. This trend was similarly seen in the r2
values of the Tm3+ complexes.
Table 5.4: Relaxivity parameters r1 and r2 (mM-1 s-1) of Dy3+ based agents 5.17b and
5.21b at pH 7.00 ± 0.03 and 10oC, 25 °C and 37oC.
p-NH2
p-H
T
r1
r2
r1
r2
10oC 0.07 3.4 0.16 8.7
25oC 0.08 2.0 0.30 7.0
37oC 0.05 0.71 0.12 3.2

The study involving complexes of Dy3+-DOTA-glyn also demonstrated that SwiftConnick theory can be used to envisage the trend in r2 with respect to the lifetime of
bound water (τm), at several temperatures.12 This is given by the equation 5.1:
r2ex = (1.8 X 10-5)

τm∆ω2

equation [5.1]

1 + τm2∆ω2
where r2ex is the transverse relaxivity due to molecular water exchange, ∆ω is the
chemical shift difference of bound water in rad s-1 and τm is the lifetime of the bound
water.13,

14

It was shown that when n = 0 and 2, the exchange rates were faster than

optimal for generating T2 contrast.11 On the other hand, when n = 3 and 4 the exchange
rate was slower, with n = 2 being optimal.11 However, no data about monoacetamides
was reported. In order to compare the Dy3+-DO3A-monoanilines, temperature studies
were carried out on the p-H complex 5.17b (one with higher r2 values) and p-NH2 5.21b
(one with lower r2 values). Results for both complexes indicated that as the temperature is
increased, the r2 decreased (Table 5.4). This highlights that the exchange rate should fall
on the fast side of the Swift-Connick plot (τm < 545 ns; between n = 0 and n = 2), as is
expected for fast inner-sphere water exchange systems.11, 15 Due to the fact that these
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complexes represent each extreme (high and low r2), it is therefore expected that all of
these Dy3+ complexes would also have fast inner-sphere exchange of water. Because the
p-H complex 5.17b gave the greatest r1 and r2 values, the substituent effect appears to be
steric in nature rather than dictated by subtle changes in the electronics of the amide arm,
given that hydrogen is the smallest substituent. The steric nature of substituent may
influence the conformation of the complex, but perhaps more likely influence the second
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Figure 5.6: (a) r1 with respect to pH at 25oC for 4mM each of 5.15b - 5.18b and
5.20b - 5.21b and (b) r2 with respect to pH at 25oC for 4mM each of 5.15b - 5.18b
and 5.20b - 5.21b.

In order to determine the potential of these complexes as the basis for development of pH
probes for the physiologically interesting range (pH < 7),5 a study was carried out with 4
mM of each complex over a pH range of 4 - 9 (Figure 5.6). Within this range, the r1
values of the complexes were mainly low at the more basic pH then increased as the pH
became more acidic.
This trend may be caused by an increase in the number of coordinated water molecules at
low pH (inner-sphere interaction).16, 17 The increase at low pH was less noticeable for the
p-NH2 5.21b and p-NO2 5.20b complexes. On the other hand, the r2 values of the
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complexes had no trend with respect to pH over the range tested. Unexpectedly, the pNMe2 complex 5.15b demonstrated a dramatic increase in relaxivity at pH 9, which may
be due to OH- catalyzed prototropic exchange.16, 17
In order to be applicable as a responsive probe, a change in relaxivity approximately 2.0
mM–1 s–1 or more is needed.18 None of the complexes met this requirement within the
biologically relevant pHs.

5.3 Conclusions
It has been shown that several Tm3+- and Dy3+-DO3A-monoanilide complexes can be
synthesized and obtained in moderate to excellent yields starting from monoalkylation of
Et3DO3A with various para-substituted anilines.
It was also demonstrated that a CEST signal could be generated from an amide proton in
the Tm3+ complexes. The amide CEST signal is slightly modulated under varying pH
conditions, by using EDGs or EWGs. Complexes containing EDGs gave higher CEST
intensities at pH 8, while those with EWGs had higher CEST intensities at pH 7. The
observed chemical shifts of the CEST signals were independent of pH but were
influenced by the nature of the para-substitutent.
It has been furthermore established that the relaxivities for the Tm3+ complexes were very
weak, while those of the Dy3+ complexes were stronger. However, the presence of either
strongly electron-donating or withdrawing groups in the Dy3+complexes, resulted in
weaker relaxivities.
The observed trends in CEST intensity and relaxivity are not simply dependent on the
electronic nature of the para-substitutent and are a result of complex interplay of metalbound water exchange rate, amide-proton exchange rate, outer sphere solvation and
conformation of the complex – contributing factors that cannot be deconvoluted in these
studies.19
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Although the complexes reported herein are not very promising as responsive contrast
agents for in vitro or in vivo use, the information gleaned is still valuable for the
development of agents that can provide a CEST signal due to amide proton(s). This
information can assist in the design of ligands to achieve agents with CEST responses
that would fall within the physiological pH range of interest (pH 6.5-7.5). One step
towards this objective would be to investigate variation of the position of substitution
with other EDGs or EWGs on the aniline ring as well as bis(amide)-bis(carboxylate)
ligands.

5.4 Supplemental Information
5.4.1 General Experimental
General synthetic details can be found in Appendix 1.
CEST and Relaxivity Experiments
CEST spectra of complexes were acquired on a 600 MHz vertical bore NMR
spectrometer, using a 15 µT, 2 s continuous wave presaturation pulse at offset
frequencies ranging from -110 to 110 ppm in steps of 1 ppm at a concentration of 10 mM
in D2O/H2O (9:1) at pH 6.00 ± 0.03, 7.00 ± 0.03 and 8.00 ± 0.03; 37 °C. T1 and T2
relaxation time constant measurements were made on a 400 MHz vertical bore NMR
spectrometer. T1 and T2 relaxation time constant measurements were made for four
different concentrations (1, 2, 4, 8 mM) of Dy3+ complexes and three different
concentrations (2, 4, 8 mM) of Tm3+ complexes in H2O. T1 relaxation time constant was
measured using an inversion recovery sequence (15-20 inversion times in the range of
200 ms – 25 s) with a minimum d1 = 5T1 to ensure full recovery (pH 7.00 ± 0.03 and
25°C). T2 relaxation time constant measurements were made using a CPMG pulse
sequence (15-20 train echo times) with a minimum d1 = 5T1 to ensure full recovery (pH
7.00 ± 0.03 and 25°C). Additional T1 and T2 temperature studies were done at 25°C and
37°C (pH 7.00 ± 0.03). VNMRJ® software of the spectrometer automatically gave the T1
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and T2 relaxation rate constants. The relaxivities were then determined by linear
regression fitting of the rate constants versus concentration in Microsoft Excel.

5.4.2 Synthetic Procedures
General procedure for monoalkylation. Et3DO3A and K2CO3 were suspended in
CH3CN (3-5 mL) and acetamides 5.1 - 5.5 dissolved in CH3CN (1.5-2.5 mL) were added.
The reaction mixture was heated to 55oC-60oC and left for overnight. Reaction mixture
was filtered and the filtrate concentrated. The crude material was purified by silica gel
column chromatography with 5% MeOH in CH2Cl2. The desired fractions were collected
and concentrated to give the desired compounds.

Triethyl

2,2',2''-(10-(2-((4-

(dimethylamino)phenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (5.6). Et3DO3A (1.027 mmol), compound 5.1 and K2CO3 (1.550 mmol
each). The title compound was obtained as a brown oil (168 mg, 27%). 1H NMR (400
MHz, CDCl3): δ 10.75 (1H, s); 7.67 (2H, d, J = 9.3 Hz); 6.55 (2H, d); 4.17 - 4.07 (8H,
m); 3.49 (2H, s); 3.33 - 1.96 (16H, m); 1.23 - 1.19 (12H, m).

13

C NMR (100 MHz,

CDCl3): δ 173.0, 169.9, 147.0, 130.0, 121.1, 112.9, 61.1, 56.8, 55.0, 51.1, 49.1, 41.1,
14.0. ESI-TOF m/z calcd for C30H51N6O7 (M+H)+, calculated 607.3819, found 607.3813.
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Triethyl

2,2',2''-(10-(2-((4-methoxyphenyl)amino)-2-

oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.7). Et3DO3A (1.039
mmol), compound 5.2 and K2CO3 (1.632 mmol each).The title compound was obtained
as a colourless oil (234 mg, 38%). 1H NMR (400 MHz, CDCl3): δ 10.93 (1H, s); 7.72
(2H, d, J = 8.7 Hz); 6.65 (2H, d); 4.17 - 4.07 (8H, m); 3.67 (3H, s); 3.50 (2H, s); 3.37 1.97 (16H, m); 1.22 - 1.17 (12H, m). 13C NMR (100 MHz, CDCl3): δ 173.0, 170.8 132.5,
121.3, 113.7, 61.1, 56.8, 55. 2, 55.0, 52.1, 48.9, 41.1, 14.0. ESI-TOF m/z calcd for
C29H48N5O8 (M+H)+, calculated 594.3503, found 594.3522.

Triethyl 2,2',2''-(10-(2-oxo-2-(phenylamino)ethyl)-1,4,7,10tetraazacyclododecane-1,4,7-triyl)triacetate (5.8). Et3DO3A (1.039 mmol), compound
5.3 and K2CO3 (1.632 mmol each). The title compound was obtained as a colourless oily
residue (211 mg, 36%). 1H NMR (400 MHz, CDCl3): δ 11.1 (1H, s); 7.84 (2H, d, J = 7.8
Hz); 7.13 (2H, t); 6.94 (1H, t, J = 7.4 Hz); 4.16 - 4.09 (6H, m); 3.55 (2H, s); 3.41 - 1.93
(16H, m); 1.24 - 1.19 (9H, m).

13

C NMR (100 MHz, CDCl3): δ 173.0, 170.9, 139.1,

128.1, 123.2, 120.0, 61.2, 56.9, 55.0, 51.4, 49.2, 14.0. ESI-TOF m/z calcd for C28H46N5O7
(M+H)+, calculated 564.3397, found 564.3399.

Triethyl

2,2',2''-(10-(2-((4-chlorophenyl)amino)-2-

oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.9). Et3DO3A (1.039
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mmol), compound 5.4 and K2CO3 (1.632 mmol each). The title compound was obtained
as a colourless oily residue (254 mg, 41%). 1H NMR (400 MHz, CDCl3): δ 11.46 (1H,
s); 7.89 (2H, d, J = 9.0 Hz); 7.13 (2H, d); 4.20 - 4.14 (6H, m); 3.65 (2H, s); 3.57-1.97
(16H, m); 1.29 -1.24 (9H, m). 13C NMR (100 MHz, CDCl3): δ 173.0, 171.2, 137.9, 128.1,
121.5, 110.1, 61.3, 57.0, 55.1, 52.1, 48.7, 14.1. ESI-TOF m/z calcd for C28H45ClN5O7
(M+H)+, calculated 598.3008, found 598.2999.

EtO
O
O
EtO

OEt
N

N

N

N

O
O
N
H

NO2

Triethyl

2,2',2''-(10-(2-((4-nitrophenyl)amino)-2-

oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate

(5.10).

Et3DO3A

(1.039 mmol), compound 5.5 and K2CO3 (1.632 mmol each). The title compound was
obtained as a yellow oily residue (171 mg, 27%). 1H NMR (400 MHz, CDCl3): δ 12.02
(1H, s); 8.13 (2H, d, J = 8.9 Hz); 8.06 (2H, d); 4.22 - 4.10 (8H, m); 3.73 (2H, s); 3.54 2.18 (16H, m); 1.30 -1.24 (9H, m). 13C NMR (100 MHz, CDCl3): δ 173.1, 172.3, 145.3,
142.8, 124.3, 119.8, 61.4, 57.2, 55.1, 52.1, 48.7, 14.1. ESI-TOF m/z calcd for C28H45N6O9
(M+H)+, calculated 609.3248, found 609.3222.

General procedure for saponification. Et3DO3A-monoanilines 5.6 - 5.9 were dissolved
in MeOH (1.5-2.5 mL) and 1M NaOH (1.5-2.5 mL) added, then heated to 60oC and left
for overnight. The reaction mixture was concentrated and neutralized with 1M HCl. The
crude was purified by size exclusion column chromatography (100% H2O) and the
desired fractions were collected and lyophilized to give the desired compounds.
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2,2',2''-(10-(2-((4-(dimethylamino)phenyl)amino)-2oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (5.11). Compound
5.6 (115 mg, 0.190 mmol). Title compound was obtained as a brown solid (110 mg,
98%). 1H NMR (400 MHz, D2O): δ 7.32 (2H, d, J =8.0 Hz); 6.68 (2H, d); 3.91 (2H, s);
3.80-2.12 (16H, m). ESI-TOF m/z calcd for C24H39N6O7 (M+H)+, calculated 523.2880,
found 523.2889.

2,2',2''-(10-(2-((4-methoxyphenyl)amino)-2-oxoethyl)1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (5.12). Compound 5.7 (170
mg, 0.286 mmol). Title compound was obtained as a brown solid (157 mg, 95%).1H
NMR (400 MHz, D2O): δ 7.38 (2H, d); 6.98 (2H, d J = 8.0 Hz)); 3.93 (2H, s); 3.89-2.78
(16H, m). ESI-TOF m/z calcd for C23H36N5O8 (M+H)+, calculated 510.2564, found
510.2569.

2,2',2''-(10-(2-oxo-2-(phenylamino)ethyl)-1,4,7,10tetraazacyclododecane-1,4,7-triyl)triacetic acid (5.13). Compound 5.8 (160 mg, 0.284
mmol). Title compound was obtained as a cream solid (149 mg, 96%).

1

H NMR (400

MHz, D2O): δ 7.59-7.36 (4H, m); 7.25 (1H, t, J = 6 Hz); 6.83 (~0.5H, t, J = 7 Hz); 3.95
(2H, s); 3.88-2.24 (16H, m). ESI-TOF m/z calcd for C22H34N5O7 (M+H)+, calculated
480.2458, found 480.2441.
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2,2',2''-(10-(2-((4-chlorophenyl)amino)-2-oxoethyl)1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (5.14).
Compound 5.9 (240 mg, 0.401 mmol). Title compound was obtained as a cream solid
(210 mg, 90%). 1H NMR (400 MHz, D2O): δ 7.54-7.33 (4H, m); 3.95 (2H, s); 3.90-2.21
(16H, m). ESI-TOF m/z calcd for C22H33ClN5O7 (M+H)+, calculated 514.2069, found
514.2073.

2,2',2''-(10-(2-((4-nitrophenyl)amino)-2-oxoethyl)1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (5.19). Compound 5.10 (115
mg, 0.189 mmol) was dissolved in MeOH (3 mL) and cooled to 5oC. NaOH (38 mg,
0.945 mmol) was added and the mixture left sirring at 5oC for 3 hrs then brought to rt and
left for overnight. The reaction mixture was concentrated and neutralized with 1M HCl.
The crude was purified by size exclusion column chromatography (100% H2O) and the
desired fractions were collected and lyophilized to give the desired compound. Title
compound was obtained as a yellow solid (105 mg, 94%). 1H NMR (400 MHz, D2O):
δ8.18 (2H, d); 7.67 (2H, d J = 9.0 Hz)); 3.94 (2H, s); 3.89-2.99 (16H, m). ESI-TOF m/z
calcd for C22H33N6O9 (M+H)+, calculated 525.2309, found 525.2316.

General procedure for metalation. Compounds 5.11 - 5.14 and 5.19 were dissolved in
H2O (2 mL) then the appropriate lanthanide chloride salts added. The pH was adjusted to
6 and the reaction mixture heated to 55oC and left for overnight.
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Thulium(III)

2,2',2''-(10-(2-((4-

(dimethylamino)phenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (5.15a). Compound 5.11 (43 mg, 0.073 mmol) and TmCl3.6H2O (30 mg,
0.073 mmol). Title compound was obtained as a brown solid (24 mg, 44%). ESI-TOF m/z
calcd for C24H36N6O7Tm (M+H)+, calculated 689.1988, found 689.2010.

Thulium(III) 2,2',2''-(10-(2-((4-methoxyphenyl)amino)2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.16a). Compound
5.12 (42 mg, 0.073 mmol) and TmCl3.6H2O (30 mg, 0.073 mmol). Title compound was
obtained as a cream solid (35 mg, 65%). ESI-TOF m/z calcd for C23H33N5O8Tm (M+H)+,
calculated 676.1671, found 676.1659.

Thulium(III)

2,2',2''-(10-(2-oxo-2-(phenylamino)ethyl)-

1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.17a). Compound 5.13 (40 mg,
0.073mmol) and TmCl3.6H2O (30 mg, 0.073 mmol). Title compound was obtained as a
cream solid (30 mg, 58%). ESI-TOF m/z calcd for C22H31N5O7Tm (M+H)+, calculated
646.1566, found 646.1588.
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Thulium(III)

2,2',2''-(10-(2-((4-chlorophenyl)amino)-2-

oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.18a). Compound
5.14 (42 mg, 0.073mmol) and TmCl3.6H2O (30 mg, 0.073 mmol). Title compound was
obtained as a cream solid (30 mg, 55%). ESI-TOF m/z calcd for C22H30ClN5O7Tm
(M+H)+, calculated 680.1176, found 680.1178.

Thulium(III)

2,2',2''-(10-(2-((4-nitrophenyl)amino)-2-

oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.20a). Compound
5.19 (43 mg, 0.073 mmol) and TmCl3.6H2O (30 mg, 0.073 mmol). Title compound was
obtained as a yellow solid (50 mg, 91%). ESI-TOF m/z calcd for C22H30N6O9Tm (M+H)+,
calculated 691.1417, found 691.1404.

Dysprosium(III)

2,2',2''-(10-(2-((4-

(dimethylamino)phenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (5.15b). Compound 5.11 (60 mg, 0.102 mmol) and DyCl3.6H2O (38 mg,
0.102 mmol). Title compound was obtained as a brown solid (46 mg, 60%). ESI-TOF m/z
calcd for C24H36N6O7Dy (M+H)+, calculated 683.1859, found 683.1874
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Dysprosium(III)

2,2',2''-(10-(2-((4-

methoxyphenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (5.16b). Compound 5.12 (59 mg, 0.102 mmol) and DyCl3.6H2O (38 mg,
0.102 mmol). Title compound was obtained as a cream solid 58 mg, 77%). ESI-TOF m/z
calcd for C23H33N5O8Dy (M+H)+, calculated 670.1543, found 670.1569.

Dysprosium(III) 2,2',2''-(10-(2-oxo-2-(phenylamino)ethyl)1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.17b). Compound 5.13 (56 mg,
0.102 mmol) and DyCl3.6H2O (38 mg, 0.102 mmol). Title compound was obtained as a
cream solid (48 mg, 68%). ESI-TOF m/z calcd for C22H31N5O7Dy (M+H)+, calculated
640.1437, found 640.1457.

Dysprosium(III) 2,2',2''-(10-(2-((4-chlorophenyl)amino)2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.18b). Compound
5.14 (59 mg, 0.102 mmol) and DyCl3.6H2O (38 mg, 0.102 mmol). Title compound was
obtained as a cream solid (36 mg, 47%). ESI-TOF m/z calcd for C22H30ClN5O7Dy
(M+H)+, calculated 674.1047, found 674.1048.
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Dysprosium(III) 2,2',2''-(10-(2-((4-nitrophenyl)amino)2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetat (5.20b). Compound
5.19 (60 mg, 0.102 mmol) and DyCl3.6H2O (38 mg, 0.102 mmol). Title compound was
obtained as a yellow solid (42 mg, 55%). ESI-TOF m/z calcd for C22H30N6O9Dy (M+H)+,
calculated 685.1288, found 685.1319.

Reduction of 5.20a,b. Compounds 5.20a,b were each dissolved in MeOH (2 mL) and
Pd/C (10 mol %) added. The suspension was purged with H2 under vacuum and left
stirring for 2 days at rt under H2. The reaction mixture was filtered and the filtrate
concentrated then redissolved in H2O and lyophilized.

Thulium(III) 2,2',2''-(10-(2-((4-aminophenyl)amino)-2oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5.21a). Compound
5.20a (30 mg, 0.040 mmol) and TmCl3.6H2O (15 mg, 0.040 mmol). Title compound was
obtained as a white solid (29 mg, 86%). ESI-TOF m/z calcd for C22H32N6O7Tm (M+H)+,
calculated 661.1675, found 661.1656.

Dysprosium(III)

2,2',2''-(10-(2-((4-

aminophenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
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triyl)triacetate (5.21b). Compound 5.20b (20 mg, 0.027 mmol) and DyCl3.6H2O (10
mg, 0.027 mmol). Title compound was obtained as a white solid (14 mg, 74%). ESI-TOF
m/z calcd for C22H32N6O7Dy (M+H)+, calculated 655.1546, found 655.1518.

5.4.3 Spectra
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S 5.2: 13C-NMR Spectrum of 5.6
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S 5.4: 13C-NMR Spectrum of 5.7
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S 5.6: 13C-NMR Spectrum of 5.8
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S 5.8: 13C-NMR Spectrum of 5.9
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S 5.10: 13C-NMR Spectrum of 5.10
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S 5.12: 1H-NMR Spectrum of 5.12
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S 5.14: 1H-NMR Spectrum of 5.14
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S 5.16: r1 relaxivity profile of 5.15a
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S 5.17: r2 relaxivity profile of 5.15a
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S 5.18: r1 relaxivity profile of 5.16a
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S 5.19: r2 relaxivity profile of 5.16a
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S 5.20: r1 relaxivity profile of 5.17a
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S 5.21: r2relaxivity profile of 5.17a
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S 5.22: r1 relaxivity profile of 5.18a
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S 5.23: r2 relaxivity profile of 5.18a
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S 5.24: r1 relaxivity profile of 5.20a
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S 5.25: r2 relaxivity profile of 5.20a
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S 5.26: r1 relaxivity profile of 5.21a
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S 5.27: r2 relaxivity profile of 5.21a
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S 5.28: r1 relaxivity profile of 5.15b
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S 5.29: r2 relaxivity profile of 5.15b
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S 5.30: r1 relaxivity profile of 5.16b
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S 5.31: r2 relaxivity profile of 5.16b
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S 5.32: r1 relaxivity profile of 5.17b
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S 5.33: r2 relaxivity profile of 5.17b
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S 5.34: r1 relaxivity profile of 5.18b
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S 5.35: r2 relaxivity profile of 5.18b
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S 5.36: r1 relaxivity profile of 5.20b
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S 5.37: r2 relaxivity profile of 5.20b
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S 5.38: r1 relaxivity profile of 5.21b
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S 5.39: r2 relaxivity profile of 5.21b
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S 5.40: Temperature profile of r1 relaxivity of 5.17b
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S 5.41: Temperature profile of r2 relaxivity of 5.17b
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S 5.42: Temperature profile of r1 relaxivity of 5.21b
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S 5.43: Temperature profile of r2 relaxivity of 5.21b
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Chapter 6
6

Synthesis Towards Modified Dy3+ and Tm3+ DOTAMtetraanilide Complexes Bearing a para-phosphonate
Monoanilide for In vivo Studies

6.1 Introduction
A previous report was made regarding the study of DOTAM-tetraanilide PARACEST
agents which were varied with regards to their para-substituents.1 This was done with the
aim of exploring the adjustment of the amide exchange rate by the presence of electronwithdrawing groups (EWGs) and electron-donating groups (EDGs). The adjustment of
the amide exchange rate in turn would affect the CEST due to amide protons.
Unfortunately, with the exception of the Dy3+ and Tm3+-p-H and -p-OMe complexes
(Figure 6.1), the other complexes were insoluble and could not be further analyzed after
synthesis.1 The solid state structure of the Tm3+-p-OMe complex revealed that the angle
between the N-Ln-N and O-Ln-O planes (α) was 27o, thus indicating a twisted square
antiprismatic (TSAP) geometry. It was also noted that the complex lacked a metal bound
water molecule and was more accurately termed as the TSAP' isomer. Additionally, the
Tm3+-p-OMe complex had an interesting feature of two CEST signals of moderate
intensities at -43 and -83 ppm, corresponding to the square antiprismatic (SAP') and
TSAP' isomers, respectively.1 These features reported for the Tm3+-p-OMe complex are
unique and so warrants further studies.

Figure 6.1: Chemical structures of some complexes discussed in this work.
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It has been reported that non-ionic complexes are more tolerable than ionic ones due to
better blood compatible viscosity and osmolality.2 Therefore, for the tetraanilide Tm3+-pOMe complex to be used in vivo (in mice or other animal models), the overall charge of
the complex needs to be reduced to neutral or close to neutral. To meet the charge
requirements, it was decided that a phosphonate group should be installed in the paraposition of the unsubstituted aniline ring. This derivative would be a lone arm on the
macrocycle, with the remaining arms being the unmodified para-substituted aniline of pOMe. The corresponding p-H complex would also be synthesized for comparison
purposes. As a result, our lanthanide metalated complexes would have an overall charge
of +1, which should be more tolerable for in vivo studies, should the opportunity present
itself. Additionally, we hoped for an increase in solubility in aqueous solvents. It is
anticipated that the presence of the two CEST signals seen in the unmodified tetraanilide
Tm3+-p-OMe complex would still be present in this modified analogue. If so, it would
allow for ratiometric analysis that would eliminate the CEST effect dependency on
concentration, thus allowing the agent to be used as a biological reporter.3,

4

The

ratiometric analysis of the unmodified tetraanilide Tm3+ -p-OMe complex was attempted
but due to solubility restrictions, no appropriate measurements could be performed.1

6.2 Results and Discussion
6.2.1 Synthesis
The synthetic route as shown in Schemes 6.1 and 6.2 represent the attempts to the
modified DOTAM tetraanilide possessing a phosphonate group. The initial reactions
attempted in order to achieve 6.4 without using a protecting group for the amino moiety
was met with difficulty. Starting with the p-I-aniline 6.1, several conditions were tried.
These included using various solvents (toluene, CH3CN), reaction times (up to 3 days),
and temperatures (90oC - 155oC). Under these conditions, multiple products were formed
including the desired compound but purification of the mixture was challenging.
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Scheme 6.1: Synthetic route to phosphonate ester electrophile.

To further optimize the desired reaction conditions whereby the phosphonate diester was
produced, several metal-catalyzed cross couplings of 6.1 and triethyl phosphite were
attempted based on literature precedence.5 NiCl2, Pd(OAc)2 and PdCl2 were used as
catalysts. However, all gave the same results as previously observed, that is, multiple
products being formed. This occurred whether or not the reaction was carried out at room
temperature or heated to high temperatures.
A model reaction with iodobenzene was performed using the PdCl2 catalyst so as to
determine whether or not the amine of 6.1 was inhibiting the progress of the desired
reaction. This reaction was successful and thus highlighted the need of a protecting group
for the amine moiety.
Following literature procedure,6 the amino group of the p-I-aniline 6.1 was protected with
an aceyl group to give 6.2. The palladium-mediated cross coupling reaction was then reattempted with 6.2 and the alkylphosphite. While this reaction was met with more
success as compared to that with the free amine, the reaction times were long and the
yields were unsatisfactory. To reduce the reaction times while possibly increasing the
yields of 6.3, microwave-assisted synthesis of the palladium-catalyzed cross coupling
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reaction was performed.7 Moderate yields of the desired phosphonate diester compound
6.3 were accomplished following purification by column chromatography.

Scheme 6.2: Synthetic attempt to obtain metalated phosphonate complexes.
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The cross-coupling reaction between palladium and the protected p-I-aniline 6.2 relies on
the Pd (II) of the catalyst being reduced to Pd (0) by the triethyl phosphite. In order for
this reduction to occur, it has been demonstrated that at least five equivalents of the
triethy phosphite is needed, in addition to heating the reaction mixture to at least 80oC.7, 8

Scheme 6.4: Proposed mechanism of palladium-catalyzed microwave-assisted
synthesis of a phosphonate diester.

The mechanism of the catalysis by Pd(0) is more complicated than the corresponding
reaction with Ni(0). This complication arises as a result of factors such as the source of
Pd(0), the types of ligands of the catalyst and the electronic and steric factors of the aryl
(or alkyl halide).9 The proposed mechanism for this cross coupling is shown in Scheme
6.4 and is derived from that of the nickel-mediated reaction.9
The amino-protecting group of 6.3 was removed and a reaction involving 6.4 and
chloroacetyl chloride was carried out to afford compound 6.5 (Scheme 6.1).
Monoalkylation of the triBoc-protected cyclen 6.6 with the electrophile 6.5 using
traditional conditions were problematic. Initial conditions were done at room temperature
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followed by heating at 50oC for up to 3 days but the reaction was quite sluggish. The
reaction was also carried out with the assistance of the microwave, initially at 60oC and
then at 80oC for up to 3 hrs. At these higher temperatures, even although the reaction
proceeded with some improvement, UPLC-MS also showed deprotected products. As
such, the subsequent monoalkylation reaction was carried out at 70oC. Additionally,
rather than separate the products at this stage, the crude reaction mixture of 6.7 was
carried forward to the deprotection step to facilitate a less complicated purification step.
Over two steps, the monoalkylated product 6.8 was obtained in low yield (Scheme 6.2).
Trialkylation of 6.8 with the unmodified aniline electrophiles of p-H (6.9) and p-OMe
(6.10) proceeded sluggishly as that of the monoalkylation and the reaction did not go to
completion. The outcome was the same whether the reaction was done for 3 days heating
at 60oC or in the microwave for 3 hrs at 80oC. Creation of an in situ iodide-containing
electrophile of 6.9 and 6.10 via a Finklestein reaction did not improve the formation of
the desired peralkylated products 6.11 and 6.12. The reaction mixture consisted mostly of
trialkylated and tetraalkylated products that were difficult to separate by silica gel column
chromatography as both products were very polar and eluted together. Purification was
also attempted by semi-preparative thin layer chromatography with a solvent system of
H2O/sec-butanol/acetic acid in 2.5:2.0.5 ratio. Those conditions also proved unsuccessful.
As a last attempt and based on the polarity of the products, HPLC purification using a C18
column was attempted. This was met with some success but the desired products 6.11 and
6.12 were obtained in low yields.
The dealkylation step of the phosphonate diesters of the peralkylated compounds 6.11
and 6.12 was the most difficult step (Scheme 6.2). Several reaction conditions were
attempted in order to cleave the ester bonds. These ester bonds were very stable under
refluxing conditions or heating in the microwave at high temperatures in concentrated
HCl.10 A reaction mixture of incomplete deakylation products ensued when TMSBr was
used at room temperature in varying solvents for prolonged reaction times.6,

11

This

phenomenon was also observed when neat TMSBr was used. Although the reaction
conditions with TMSBr produced some of desired phosphonate compound, UPLC-MS
also indicated various bromide adducts of these products, which were still present even
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after neutralization with NaOH and 2 days of dialysis. This was the norm when more than
90% TMSBr was used. Quenching the reaction with CH3OH as typically done after
concentration of the reaction mixture,6 led to decomposition products.
As a result of the challenges faced during removal of the phosphonate diesters of 6.11
and 6.12, it was decided that metalation of the diesters 6.11 and 6.12 as seen in Scheme
6.3 should be pursued so as to be able to preliminarily characterize the complexes based
on their magnetic properties. This approach does not represent an ideal situation,
considering that these complexes would still have a +3 charge and the charge
requirements for future in vivo studies would not be met.

6.3 Conclusions and Future Work
The synthesis of DOTAM-para-substituted tetraanilide Dy3+ and Tm3+ complexes with
one aniline arm bearing a phosphonate group in the para-position of the aniline ring and
the remaining arms containing p-OMe or p-H was attempted. This modification was
based on published results regarding the intriguing observation of two amide CEST
signals in the unmodified tetraanilide Tm3+-p-OMe complex.1 The purpose of the
phosphonate group was to reduce the overall charge of the complex for prospective in
vivo studies. Unfortunately, the synthesis was fraught with difficulties such as low yields
and unsuccessful reactions. Consequently, at this time, the desired target complexes
cannot be attained.
The inability to acquire the desired target phosphonate metal complexes, necessitated
temporary alteration of the target metalated complexes to that containing the phosphonate
diesters. Once these precursor compounds are obtained in yields sufficient for metalation,
the lanthanides Dy3+ and Tm3+ will be incorporated into the these ligands containing pOMe or p-H. At this juncture, comparative evaluation of the magnetic properties of these
complexes similar to that carried out for the unmodified tetraanilide complexes for which
no inner sphere water was present will be performed.1
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More importantly, the condition for efficient removal of the phosphonate diester needs to
be determined. This may involve changing the type of alkyl groups of the phosphonate
diester. Once this has been accomplished, metalation with the desired lanthanides can be
carried out. The magnetic properties of the complexes can then be evaluated and
compared to both the unmodified DOTAM tetraanilide complexes and those having the
phosphonate diester present. Depending on the results obtained, in vivo assessments of
the modified tetraanilides containing the phosphonate group may be completed.

6.4 Supplemental Information
6.4.1 General Experimental
General synthetic details can be found in Appendix 1.

6.4.2 Synthetic Procedures

Diethyl (4-acetamidophenyl)phosphonate (6.3). Triethylphosphite (1.25 mL,
7.173 mmol) and PdCl2 (0.159 g, 0.897 mmol) were added to a solution of 6.2 (1.17 g,
4.483 mmol) in CH3CN (18 mL) in a 20 mL microwave vial which was then sealed. The
mixture was irradiated at 100oC and maintained for 3 h with stirring in a Biotage
Initiator® microwave reactor. The temperature was monitored by external IR temperature
sensor. After 3 h, the reaction was checked by TLC and UPLC-MS and the solution was
transferred to a round bottom flask for concentration under reduced pressure. The crude
product was purified by column chromatography (silica, 1:1 EtOAc/hexanes then 5%
MeOH in CH2Cl2). The title compound was obtained as a yellow sticky solid (1.03 g,
85%). 12 1H NMR (400 MHz, CDCl3): δ 8.21 (1H, s); 7.78 -7.63 (4H, m); 4.18-3.99 (4H,
m (2 x dq), 3JPH = 10.0 Hz); 2.21 (3H, s); 1.32 (6H, t, J = 7.0 Hz). 13C NMR (100 MHz,
CDCl3): δ 169. 5, 142.7, 132.7, 119.2, 62.2, 24.4, 16.2. 31P NMR (161.97 MHz, CDCl3):
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δ 18.8. ESI-TOF m/z calcd for C12H19NO4P (M+H)+, calculated 272.1052, found
272.1043.

Diethyl 4-aminophenylphosphonate (6.4). Sodium (0.245 g, 10.64 mmol)
dissolved in dry EtOH (21 mL) under N2 was added to a solution of 6.3 (1.03 g, 3.80
mmol) in dry EtOH (10 mL) and the reaction mixture was refluxed under nitrogen
atmosphere for overnight. After the reaction was complete (monitored by TLC and
UPLC-MS), the solvent was removed under reduced pressure and the crude black
mixture then suspended in CHCl3 and was washed with H2O. The organic layer was
collected and dried over Na2SO4, filtered and concentrated under reduced pressure. The
crude product was purified by column chromatography (silica, 20-100% EtOH in
CHCl3). The product 6.4 was obtained as a yellow sticky solid (0.740 g, 85%).11 1H NMR
(400 MHz, CDCl3): δ 7.61 - 7.53 (2H, dd, J = 8 Hz, 3JPH = 12.0 Hz); 6.72 - 6.66 (2H, dd,
4

JPH = 3.0 Hz); 41.5 -. 3.96 (4H, m (2 x dq), 3JPH = 10.0 Hz); 1.30 (6H, t, J = 7.0 Hz). 13C

NMR (100 MHz, CDCl3): δ 133.7, 133.6, 114.2, 114.1, 61.7, 61.7, 61.7, 16.3, 16.3. 31P
NMR (161.97 MHz, CDCl3): δ 21.4. ESI-TOF m/z calcd for C10H17NO3P (M+H)+,
calculated 230.0946, found 230.0941.

Diethyl 4-(chloroacetamido)phenylphosphonate (6.5). A suspension of
K2CO3 (0.536 g, 3.876 mmol) in a solution of 6.4 (0.740 g, 3.23 mmol) in CH3CN
(12mmL) was cooled to 0oC. A solution of chloroacetyl chloride (0.31 mL, 3.876 mmol)
in CH3CN (2 mL) was then added dropwise. The reaction mixture was slowly warmed to
room temperature and then stirred overnight (monitored by TLC and HR-ESI-MS). The
reaction mixture was filtered, the filtrate collected and concentrated under reduced
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pressure. The crude product was used without further purification in the next step.11 The
resulting oil was evaporated with toluene three times to give the crude product as a
yellow solid (0.756 g, 77%) which was used without further purification in the next step.
1

H NMR (400 MHz, CDCl3): δ 8.68 (1H, s); 7.84 - 7.75 (2H, dd, J = 9 Hz, 3JPH = 13.0

Hz); 7.74 - 7.68 (2H, dd, 4JPH = 3.0 Hz); 4.22 (2H, s); 4.19-4.03 (4H, m (2 x dq), 3JPH =
10.0 Hz); 1.32 (6H, t, J = 7.0 Hz). 13C NMR (100 MHz, CDCl3): δ 164.5, 140.8, 140.8,
133.0, 132.9, 119.6, 119.4, 62.5, 62.4, 42.9, 16.3, 16.2. 31P NMR (161.97 MHz, CDCl3):
δ 18.3. ESI-TOF m/z calcd for C12H18ClNO4P (M+H)+, calculated 306.0662, found
306.0652.

Diethyl

(4-(2-(1,4,7,10-tetraazacyclododecan-1-

yl)acetamido)phenyl)phosphonate (6.8). K2CO3 (0.423 g, 3.06 mmol), NaI (0.238 g,
1.591 mmol), 6.5 (0.486 g, 1.591 mmol) and 6.6 (0.723 g, 1.530 mmol) were suspended
in acetone/CH3CN (2:16 mL) in a 20 mL microwave vial which was then sealed. The
mixture was irradiated at 70oC and maintained for 3h with stirring in a Biotage Initiator®
microwave reactor. The temperature was monitored by an external IR temperature sensor.
After 3 h, the reaction was checked by HR-ESI-MS and TLC and the mixture was
filtered. The filtrate was collected and concentrated under reduced pressure. The crude
product 6.7 was used without further purification in the next step.
Crude 6.7 was dissolved in CH2Cl2 (4 mL) and an equal volume of TFA added. The
reaction mixture was left stirring for 3.5 hrs at room temperature (monitored by UPLCMS). The crude product was purified by column chromatography (silica, 1.5:5:93.5
NH4OH/MeOH in CHCl3). The product 6.8 was obtained as an orange sticky solid (0.561
g, 83%). 1H NMR (400 MHz, CD3OD): 7.83 - 7.77 (2H, dd, J = 9 Hz, 4JPH = 3.0 Hz);
7.75 - 7.67 (2H, dd, 3JPH = 13.0 Hz,); 4.16 - 4.01 (4H, m (2 x dq), 3JPH = 10.0 Hz); 3.67
(2H, s); 3.30-3.14 (16H, m); 1.31 (6H, t, J = 7.0 Hz). 13C NMR (100 MHz, CD3OD): δ
163.3, 133. 8, 121.0, 116.8, 63.9, 57.5, 51.6, 45.9, 44.7, 44.2, 43.9, 39.5, 16.7. 31P NMR
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(161.97 MHz, CD3OD): δ 19.1. ESI-TOF m/z calcd for C20H36N5O4P (M+H)+, calculated
442.2583, found 442.2590.

General procedures for synthesis of tetra-substituted cyclen. Starting material 6.8,
electrophiles 6.9 or 6.10 and K2CO3 were suspended in CH3CN in a 20 mL microwave
vial which was then sealed. The mixture was irradiated at 80oC and maintained for 3 h
with stirring in a Biotage Initiator® microwave reactor. The temperature was monitored
by an external IR temperature sensor. After 3 h, the reaction was checked by HR-ESI-MS
and the mixture was filtered and the filtrate collected and concentrated under reduced
pressure. The crude product was first purified by column chromatography (silica gel, 510% MeOH in CH2Cl2, then 100% EtOH) then by HPLC (C18, gradient over 19 mins
99:1 to 45:55 H2O/CH3CN). The fractions were concentrated to reduce the volume then
lyophilized.

Diethyl

(4-(2-(4,7,10-tris(2-oxo-2-

(phenylamino)ethyl)-1,4,7,10-tetraazacyclododecan-1yl)acetamido)phenyl)phosphonate (6.11). Starting material 6.8 (0.250 g, 0.566 mmol),
electrophile 6.9 (0.384 g, 2.264 mmol) and K2CO3 (0.313 g, 2.264 mmol) were
suspended in CH3CN (6 mL). The product 6.11 was obtained as a yellow oil (0.105 g,
22%). 1H NMR (400 MHz, CD3OD): δ 7.81 - 6.76 (17H, m); 6.71 - 6.30 (2H, m); 4.42 3.43 (20H, m); 3.21-2.91 (8H, m); 1.28 (6H, m).

31

P NMR (161.97 MHz, CD3OD): δ

19.49. ESI-TOF m/z calcd for C44H58N8O7P (M+H)+, calculated 841.4166, found
841.4157.
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Diethyl

(4-(2-(4,7,10-tris(2-((4-

methoxyphenyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1yl)acetamido)phenyl)phosphonate (6.12). Starting material 6.8 (0.250 g, 0.566 mmol),
electrophile 6.10 (0.452 g, 2.264 mmol) and K2CO3 (0.313 g, 2.264 mmol) were
suspended in CH3CN (8 mL). The product 6.12 was obtained as a cream solid (0.195 g,
37%). 1H NMR (400 MHz, CD3OD): δ 7.66 - 6.93 (12H, m); 6.66 (4H, s); 4.33 - 3.86
(10H, m); 3.82 - 3.56 (19H, m); 3.28-3.05 (8H, m); 1.29 (6H, m).

31

P NMR (161.97

MHz, CD3OD): δ 19.34. ESI-TOF m/z calcd for C47H64N8O10P (M+H)+, calculated
931.4483, found 931.4448.

6.4.3 Spectra
S 6.1: 1H-NMR Spectrum of 6.3
O
HN

PO(OEt) 2
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C-NMR Spectrum of 6.3
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S 6.2: 13C-NMR Spectrum of 6.3
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S 6.3: 31P-NMR Spectrum of 6.3
O
HN

PO(OEt) 2

188

S 6.4: 1H-NMR Spectrum of 6.4
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S 6.6: 31P-NMR Spectrum of 6.4
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S 6.8: 13C-NMR Spectrum of 6.5
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S 6.12: 31P-NMR Spectrum of 6.8
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S 6.16: 31P-NMR Spectrum of 6.12
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Chapter 7
7

Conclusions and Future Work

The Gd3+-based T1 relaxation agents currently used in clinical settings are limited in the
amount of anatomical information they provide during imaging. This low sensitivity has
led to the need to design and synthesize MRI contrast agents that will be better at
providing information regarding physiological changes such as temperature and pH. The
studies described in this body of work primarily sought to improve signal generation and
sensitivity, in a variety of metal complexes by PARACEST. This area of research
represents a part of an ongoing theme within the Hudson laboratory, that is, the synthesis
of DOTAM-based lanthanide complexes for potential clinical applications in MRI, of
which I was a part of over the past four years. For thorough analysis of the complexes
synthesized, the relaxometric properties of the complexes were additionally investigated.
The PARACEST and relaxometric data reported here for the assortment of lanthanides
and transition metals complexes studied demonstrate the progress, achievements as well
as unforeseen failures on the path towards the aforementioned goals.
The studies began by synthesizing and evaluating lanthanide complexes of DOTAM
analogues bearing a para-nitrophenol group that could undergo reversible binding to the
metal center in a pH dependent manner. With the remaining three arms of the complexes
being the same, this overall design made the complexes asymmetric. As seen in Chapter
2, the PARACEST results for the lone Tb3+ complex indicated that pH dependent
reversible binding was indeed possible. The increased relaxivity of the Gd3+ complex at
acidic pH implied a complex combination of factors. The results of this slight pH
dependent modulation of PARACEST and relaxivity suggests that tuning of the labile
arm is needed to produce possible contrast agents with the desired increase in
physiological pH sensitivity. This tuning may be accomplished by varying the electron
density of the labile arm.
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The original goal of the work in Chapter 3 was the symmetric and asymmetric
rigidification of the DOTAM scaffold, in order to increase the PARACEST signal
generation through preferential formation of the desired SAP isomer. The desired ligands
were to be tetraaza macrocycles consisting of one or two fused cyclohexane rings.
However, the final complexes (consisting of bicyclic hexaaza macrocycles) were more
rigidified than originally desired. Since the ligands deviated from the DOTA-based
design upon which the definition of SAP and TSAP is based on, these definitions are
therefore not applicable to these new macrocyclic ligands. These ligands were found to
be selective for the smaller transition metals. The absence of PARACEST signals in these
transition metal complexes demonstrated the negative impact that rigidity of that form
(and possibly steric bulk by those cyclohexyl groups) has on the exchange rate. In order
to observe a CEST signal, reduction in the level of rigidity of the structures is likely
needed.
The Dy3+ and Tm3+ DOTAM tetraanilides of Chapter 4 contained varying parasubstituents that would limit T2 exchange and increase PARACEST pH measurements
that are amide-based. This limitation of T2 exchange was possible owing to the four
aromatic rings of the acetamide pendant arms, which provided steric bulk to the complex
and blocked access of water to the metal center. This absence of a metal bound water for
the Tm3+ aniline agents increased the sensitivity of PARACEST imaging and produced
appreciable amide PARACEST contrast without decreasing image signal. These results
have good implications for in vivo PARACEST imaging which may benefit by
combining the features of the highly shifted amide CEST signal (observed in the Tm3+ -pOMe complex) and long T2 times.
Due to the low solubilities of a majority of the complexes in Chapter 4 that prohibited
them from being fully studied, para-substituted monoanilide Dy3+ and Tm3+ DO3A
complexes were synthesized and investigated (Chapter 5). The presence of EDGs and
EWGs affected the pH at which the maximum PARACEST effect is observed. This
feature is an advantage for developing biologically sensitive pH PARACEST probes. To
further maximize this feature, bis(amide)-bis(carboxylate) ligands complexes may be
investigated, along with varying the position of EDGs and EWGs on the aniline ring.
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The final chapter dealt with the endeavours made to synthesize biocompatible DOTAM
tetraanilides complexes containing a para-phosphonate monoanilide arm. These
complexes were to be based on the Dy3+ and Tm3+ complexes of -p-H and-p-OMe
tetraanilides that were evaluated in Chapter 4. Such efforts involved synthesizing
complexes that had one of the four aniline rings contain a phosphonate group in the paraposition. The synthetic procedure to remove the diesters of the phosphonate group of the
ligands has proved to be very challenging and as such, the synthesis is still ongoing. Once
the desired complexes have been obtained, the magnetic properties of the complexes can
then be evaluated and compared to the unmodified DOTAM tetraanilide complexes.
Due to the unanticipated complications faced, vital lessons were learned and highlighted
regarding the significance of structural design for ligands that are to be used as metal
chelates for MRI contrast agents. By suitably adapting and building on each stratagem
reported here or by combining them, complexes may be generated that can be customized
for different applications. It is important to ensure that these new agents will possess high
kinetic and thermodynamic stabilities, have low toxicities and exhibit their desired
imaging properties in the clinically relevant magnetic field strengths. This research is
important because it has answered questions, compared differences and similarities in
data and of course, created expectations. Current and future researchers seeking to
optimize various MRI contrast agents may use the work described here as a guide in the
expansion of more sensitive and specific MRI contrast agents.
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Appendices
Appendix 1: General Considerations
A.1.1 General Experimental Considerations
All solvents were used as purchased unless otherwise stated, except for dioxane (dried by
passing through columns of activated Al2O3) and water (18.2 MΩ⋅cm-1 deionized).
Solvents were removed under reduced pressure in a rotary evaporator. Aqueous solutions
were lyophilized. Flash column chromatography (FCC) was carried out using silica gel
(SiO2; mesh size 230–400 Å). Thin-layer chromatography (TLC) was carried out on an
Al backed silica gel plate with compounds visualized by 254 nm UV light.

Size

exclusion chromatography (SEC) was carried out on Bio-Gel P2, 45–90 μm mesh resin.
Dialysis was performed against water using a cellulose membrane with molecular weight
cut off at 500 Da.
NMR spectra were recorded on a 400 MHz spectrometer; for 1H (400 MHz), chemical
shift values (δ) are referenced relative to the residual proton in the deuterated solvents as
follows: CDCl3 (7.26 ppm), D2O (4.75 ppm), CD3OD (3.31 ppm), DMSO-d6 (2.49 ppm);
13

C NMR (125 MHz): CDCl3 (77.0 ppm), CD3OD (49.0 ppm), DMSO-d6 (39.5 ppm);

31

P

NMR (161.97 MHz). Mass spectra (MS) were obtained using electrospray ionization
(ESI). UV-visible absorption spectra were recorded over a range of 190 - 800 nm using a
Cary 300 Bio UV-Visible Spectrophotometer. Samples were placed in a 10 mm quartz
cuvette. Microwave reactions were performed in a Biotage® MW reactor using sealed
glass vials. Melting point (m.p.) was recorded in capillary tubes using a Gallenkamp
Variable Heater.
The effective magnetic moment (μeff) was calculated by using the Evans’ method.1, 2 Five
millimolar of metal complex and 5 % t-butanol by volume was placed in a capillary tube
which was then placed in an NMR tube containing 5 % by volume t-butanol in D2O. The
concentration of the metal complexes was determined by preparation of stock solutions of
complex. The μeff was calculated at 298 K (T) from NMR data, using the following
equations:
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Χg = (-3Δf)/(4πfm) +Χ0 + [Χ0 (d0-ds)]/m
μeff = 2.84 (ΧmT)1/2

1
2

The mass susceptibility of solute (Χg) was calculated by obtaining the observed
frequency shift of the reference (Δf ) in Hz, the spectrometer frequency (f) in Hz, the
mass of the substance per cm3 of solution (m), and the mass susceptibility of solvent D2O
(Χ0= -0.6466 x 10-6 cm3/g ). The last term is neglected due to the minimal contribution
to mass susceptibility of solute, in which do is density of the solvent and ds is density of
the solution in g/cm3. The molar susceptibility (Χm) is the product of Χg multiplied by the
molecular weight of the metal complex studied.
(1R, 2R)-cyclohexane-1,2-diamine tartrate, bromoacetyl bromide, ethylenediamine, LiBr
and 1M BH3 in THF were purchased from Sigma Aldrich. K2CO3 and ZnCl2 were
purchased from Fisher Scientific. CoCl2.6H2O (98%) was purchased from Lancaster
Chemicals. Lanthanide salts and transition metals salts were purchased from Strem
Chemicals. Compounds 2.33, 3.44, 3.154, 5.1 - 5.55, Et3DO3A6, 6.27, 8, 6.69, 6.95 and
6.105 were synthesized as previously. Compound ethyl (2-chloroacetyl)glycinate 3.7 was
produced by a former laboratory member.

A.1.2 General Crystallographic Considerations
The sample was mounted on a Mitegen polyimide micromount with a small amount of
Paratone N oil. All X-ray measurements were made on a Bruker Kappa Axis Apex2
diffractometer at a temperature of 110 K. The unit cell dimensions were determined from
a symmetry constrained fit of 9608 reflections with 5.16° < 2q < 76.3°. The data
collection strategy was a number of w and j scans which collected data up to 84.758°
(2q). The frame integration was performed using SAINT.10 The resulting raw data was
scaled and absorption corrected using a multi-scan averaging of symmetry equivalent
data using SADABS.10
The structure was solved by direct methods using the SIR92 program.11 All nonhydrogen atoms were obtained from the initial solution. The organic hydrogen atoms
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were introduced at idealized positions and were allowed to refine isotropically. The
positions of the hydrogen atoms on the water molecule were obtained from a difference
Fourier map. The O—H bond lengths and the H···H distance were restrained to
chemically reasonable distances. The isotropic displacement parameters for the water
bound hydrogen atoms were allowed to refine. The structural model was fit to the data
using full matrix least-squares based on F2. The calculated structure factors included
corrections for anomalous dispersion from the usual tabulation. The structure was refined
using the SHELXL-2013 program from the SHELXTL program package.12 Graphic plots
were produced using the NRCVAX program suite.13 Additional information and other
relevant literature references can be found in the reference section of this website
(http://xray.chem.uwo.ca).
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